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ABSTRACT 
Ovarian cancer (OC) is the second most common gynecologic cancer; 
however it is responsible for the most gynecologic cancer-related deaths.  
Apoptosis evasion is an important mechanism in OC tumorigenesis, and the 
prototypic anti-apoptotic protein, B-cell lymphoma 2 (Bcl-2), is often 
overexpressed in OC tumors.  Gaining a better understanding of the 
mechanism(s) behind Bcl-2 overexpression and potential extra-anti-apoptotic 
functions of Bcl-2 could elucidate the importance of elevated Bcl-2 in OC.  In the 
current study, I show through immunohistochemical analysis of normal, benign, 
and OC tissue sections, that both epithelial and stromal Bcl-2 expression 
decreases with OC progression.  However, the number of Bcl-2-positive 
lymphocyte nests and the size of these lymphocyte nests increase dramatically 
with OC progression.  Additionally, this study shows that lysophosphatidic acid 
(LPA), a glycerophospholipid frequently elevated in serum and ascites fluid of OC 
patients, upregulates Bcl-2 in OC cells.  Bcl-2 enzyme-linked immunosorbant 
assay (ELISA), western blot analysis, reverse transcriptase polymerase chain 
reaction (RT-PCR), and luciferase reporter assays reveal that LPA increases Bcl-
2 promoter, messenger RNA (mRNA), and protein levels in OC cells, but not in 
normal immortalized ovarian surface epithelial (IOSE) cells.  LPA also increases 
secreted levels of Bcl-2.  In vitro human umbilical vein endothelial cell (HUVEC) 
tube formation assays show that OC-derived Bcl-2 or recombinant human (rh) 
xii 
 
Bcl-2 promotes aberrant formation of tube-like structures.  Though extracellular 
Bcl-2 does not affect HUVEC cell viability, it may cause aberrant tube formation 
by inhibiting HUVEC migration.  Finally, Bcl-2 ELISA reveals that urinary Bcl-2 
levels in OC patients are higher than those in normal individuals and patients 
with benign gynecologic disease.  Urinary Bcl-2 also complements serum CA125 
when the two are compared in parallel samples.  Furthermore, urinary Bcl-2 
decreases following cytoreductive surgery.  Altogether, the results suggest that 
Bcl-2 is important in OC tumorigenesis and angiogenesis.  Additionally, urinary 
Bcl-2 may be a valuable non-invasive biomarker for OC diagnosis and/or 
screening.  Consequently, further elucidation of mechanisms of Bcl-2 
overexpression and its extra-apoptotic functions could lead to improved 
treatment and diagnostic strategies for OC patients. 
1 
 
 
 
 
 
 
CHAPTER I: 
INTRODUCTION 
 
Ovarian Cancer 
Ovarian cancer (OC) is the deadliest disease affecting the female genital 
tract and ranks fifth in causes of cancer related death in women in the United 
States.  For 2010, the American Cancer Society predicts that the United States 
will have an estimated 21,880 new cases of OC and 13,850 deaths due to OC 
[1].  The OC annual worldwide incidence and mortality has been estimated to be 
190,000 and 114,000 respectively [2].  According to the American Cancer 
Society, a woman has a 1.4% (1 in 72) chance of developing OC during her life 
and a 1.05% chance of dying from the disease [3].  A woman’s risk of developing 
OC increases with age, particularly after menopause.  Approximately 90% of the 
women who get OC are over the age of 40, and over half of all OCs occur in 
women over the age of 63 [3]. 
 
Ovarian Surface Epithelium 
The ovaries are a pair of almond-shaped reproductive glands found on 
each side of a woman’s uterus.  Each ovary is surrounded by a fibrous tunica 
albuginea, which is covered externally by a layer of cuboidal epithelial cells:  the 
ovarian surface epithelium (OSE).  The OSE is mesodermally derived and, in 
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early embryonic development, forms part of the lining for the intraembryonic 
coelom, termed the coelomic epithelium.  The gonadal ridge is covered by this 
coelomic epithelium, which has the capacity to differentiate along several 
pathways.  The Mullerian ducts develop as invaginations of the coelomic 
epithelium and give rise to the epithelial lining of the future fallopian tubes, 
uterus, and upper vagina [4].  As the coelomic epithelium proliferates, it forms 
cords that infiltrate the ovarian cortex and give rise to the granulosa cells in the 
primordial follicles [4].  The OSE overlies the follicles and the two are separated 
by ovarian stroma.  The OSE and stroma are separated by a basement 
membrane.  The OSE and basement membrane have a tenuous attachment, 
which can be disrupted by the slightest of mechanical forces [4]. 
 
The Origins of OC 
The OSE was originally coined the term germinal epithelium which is a 
misnomer because it does not give rise to ova [5].  In adult females, the OSE is a 
monolayered squamous-to-cuboidal epithelium, which ruptures during ovulatory 
cycles, allowing a mature follicle to escape, and must, therefore, undergo wound 
repair while exposed to estrogen-rich follicular fluid [6, 7].  OC can arise from 
ovarian germ cells, connective tissue that generates reproductive hormones in 
the ovaries (also known as the stroma), or the epithelial ovarian lining.  Of these 
origins, the most common is the OSE; therefore the most common form of OC is 
epithelial ovarian cancer (EOC) [1, 7], and there are several hypotheses on the 
mechanisms by which EOC arises.   
3 
 
The most widely accepted hypothesis is the “incessant ovulation” theory, 
which suggests that surface epithelial ovarian neoplasms are the result of chronic 
ovulation [7].  Repair of the ruptured OSE is initiated by follicular fluid, plasma, 
cell debris, and surface epithelial cells which form a gel-like clot [8].  Invasion of 
the clot by connective tissue fibers creates a scaffold for neighboring surface 
epithelial cells, which migrate centripetally and cover the ovulatory wound in 
three to five days.  In the rabbit, the luxuriant reparative response of the OSE 
often leads to the formation of papillary and cord-like growths [9].  In humans, the 
repeated wound and healing process of the OSE during ovulation, along with its 
ability to internalize potentially carcinogenic agents entering the peritoneal cavity 
through the reproductive tract [10], may cause dysplasia in the epithelial ovarian 
lining and eventually give rise to EOC.  Reduced lifetime ovulations have been 
related to lowering a woman’s risk of developing EOC [11].  Factors such as 
early menarche, late menopause, nulliparity/low parity (with or without oral 
contraceptives), hormone replacement therapy in menopause, family history of 
breast or OC, and diets high in meat and fats have been reported to increase the 
risk of a woman getting OC in her lifetime [12].   
The second, less accepted, hypothesis about the origin of EOC is the 
“gonadotrophin” theory which proposes that EOC arises from the formation of 
inclusion cysts derived from invaginations of the OSE into the ovarian stroma [7].  
Increased estrogen production, due to elevated levels of follicle stimulating 
hormone and luteinizing hormone, contributes to malignant transformation by 
stimulating the inclusion cyst epithelium to undergo rapid cell division [13].  
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Because both age-related frequencies of EOC and gonadotrophin concentrations 
are considerably high in early menopause, this is the time when gonadotrophin-
related ovarian carcinogenesis seemingly occurs [14].   
Lastly, an exfoliation theory has recently been described in which 
(pre)malignant lesions are formed when exfoliated tubal epithelial cells become 
entrapped within an ovarian stigma during the ovulatory process and undergo 
genetic changes during mitosis [15].  This theory is based on several studies in 
which preneoplastic lesions were found present in a high number of 
prophylactically removed Fallopian tubes and findings that inclusion cysts in the 
ovaries were often lined by cells that were indistinguishable from epithelial cells 
lining the Fallopian tube [16-18].  These findings are not surprising given the 
OSE undergoes a transformation to a Müllerian-type epithelium in ovarian 
carcinomas while the Fallopian tubes have a native Müllerian epithelium [19].  
Macroscopically normal Fallopian tubes in women who are predisposed to 
developing OC commonly have hyperplastic and/or dysplastic changes upon 
histological examination of their Fallopian tube epithelium [18].  These changes 
include a ‘p53 signature’, described as strongly p53-positive, benign-appearing 
epithelium in the distal Fallopian tube arising from a genotoxic injury such as 
ovulation [20, 21].  Areas within Fallopian tubes containing a p53 signature can 
then undergo cell proliferation and develop into tubal intraepithelial carcinoma 
which can then expand in the Fallopian tube or metastasize to the peritoneum or 
ovarian surface as a serous carcinoma [20].  To date, no single origin for EOC 
has been determined, however, studies support all three theories. 
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Histologic Subtypes and Staging of Ovarian Tumors 
All epithelial ovarian tumors demonstrate characteristics similar to those of 
the Müllerian epithelium; however, they differ greatly in histopathologic features 
[22].  There are four main histological subtypes of OC – serous, mucinous, 
endometrioid, and clear cell.  Epithelial cells in serous tumors resemble those of 
the fallopian tubes.  Given that serous tumors are the most common presentation 
of ovarian neoplasm, they account for 50-60% of primary epithelial ovarian 
tumors [23].  Mucinous tumor cells are similar to either endocervical or colonic 
epithelium.  They are cystic tumors with small chambers lined with mucin-
secreting epithelial cells.  They make up about 8-10% of primary epithelial 
ovarian tumors [23].  Endometrioid tumor cells bear resemblance to endometrial 
glands of the endometrium [23] and comprise about 10% of ovarian carcinomas 
[24].  Clear cell carcinomas are composed of hobnail cells with clear cytoplasm.  
These rare tumors account for only 5% of all ovarian tumors [24]. Less commonly 
occurring OC subtypes include undifferentiated, mixed epithelial type, and 
Brenner tumors. 
Upon diagnosis, OC is staged according to the degree of tumor spread.  
This is one of the best determinants for treatment and prognosis.  Ovarian 
tumors are staged according to the criteria set forth by the International 
Federation of Gynaecology (FIGO) [25].  Tumors in stage I have growth confined 
to the ovaries.  Stage II tumors are limited to the pelvis.  Tumors classified as 
stage III have growth extending to the abdominal cavity.  Lastly, stage IV tumors 
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have metastases to distant sites.  Ovarian tumors are also given a histological 
grade according to their architectural and nuclear abnormalities.  Grade I tumors 
are well differentiated.  Grade II tumors are moderately differentiated.  Grade III 
tumors are poorly differentiated.  Quite naturally, women presenting with tumors 
of a higher grade and stage tend to have a poor prognosis.   
 
Diagnostic Tools for OC 
Significance of Early Detection of OC 
Women diagnosed with OC have an overall 5-year survival rate of only 
45% [1, 7].  There is a dramatic increase to a 5-year survival rate of 94% when 
OC is diagnosed at an early stage, but this only occurs in 19% of reported cases 
[7].  Among women with advanced OC which has metastasized at the time of 
diagnosis, the survival rate declines sharply to about 28% [26].  This is generally 
attributed to the fact that OC is often asymptomatic and there is no screening 
marker available for use in the general public.  Late diagnoses result in 
discovering the disease after it has metastasized to other areas of the body, in 
turn, making it more difficult to treat.  Because of this, a diagnostic test is greatly 
needed for OC that has high sensitivity as well as specificity.  CA125 is currently 
the only Food and Drug Administration (FDA)-approved blood test for the 
detection of OC.  Despite advances in research, the outlook of OC detection at 
early stages remains bleak.  When diagnosed in stage I, currently available 
therapy can cure 90% of OC cases.  On the other hand, 20% or less stage III and 
stage IV OC cases can be cured.  Currently, only about 20% of OCs are 
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diagnosed in stage I, indicating a need for detection of preclinical disease at an 
earlier stage [7].  Research suggests that occult primary tumors spend over 4 
years as in situ, stage I/II cancers and about 1 year as stage III/IV cancers prior 
to becoming clinically apparent [27].  Detection of OC at the preclinical stage may 
help improve its cure and survival rates. 
 
Criteria for Early Detection Screening 
Ideally, screening for early detection of disease is most useful if there is a 
pre-symptomatic stage where the treatment is more effective than if given after 
symptoms emerge.  Effective screening should be readily available, acceptable 
to patients, and reasonably inexpensive.  Of most importance, the screening 
tests must have a sensitivity high enough to detect a significant portion of all 
existing cases in the population while having a sufficiently high specificity and 
positive predictive value (PPV) to avoid generating an excessive number of false-
positives.  The consequence of a positive screening test for OC results in some 
type of surgical intervention such as a laparoscopy or laparotomy.  Given the low 
incidence of OC, even in postmenopausal women, of only 1 in 2500 women per 
year, an ideal screening strategy would have a sensitivity greater than 75% for 
early stage disease with a specificity of 99.6% to yield a positive predictive value 
of 10% [28].  This means that for every 10 laparotomies performed, one would 
result in OC detection.     
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Screening Strategies 
Cancer antigen (CA) 125 has been the most widely studied OC marker for 
over two decades.  CA125 is expressed by fetal amniotic and coelomic 
epithelium.  It is expressed in adult tissues derived from coelomic (pericardium, 
peritoneum, and mesothelial cells of the pleura) and Müllerian epithelium (tubal, 
endocervical, and endometrial).  CA125 is not expressed in the surface 
epithelium of normal fetal and adult ovaries; however, it is present in metaplastic 
areas, papillar excrescences, and inclusion cysts [29].  The CA125 antigen 
carries two major antigenic domains:  A (binds monoclonal antibody OC125) and 
B (binds monoclonal antibody M11) [30].  The original clinical assay for serum 
CA125 quantification was a homologous assay that only utilized the OC125 
antibody.  The current CA125 immunoassay (CA125 II) is a heterologous assay 
that uses both the OC125 and M11 antibodies.  The current assay has a reduced 
interassay variation and is, therefore, preferred over the original homologous 
assay [31].  Investigations in the use of CA125 as a biomarker for OC began 
when CA125 levels over 35 U/mL were observed in ~83% of patients with EOC 
[32, 33].  Elevated CA125 levels were later found to be present in women 5 years 
prior to their diagnosis of OC, suggesting that CA125 may be of use as a marker 
of disease in the preclinical asymptomatic phase of OC [34].  Elevated serum 
CA125 levels are most strongly associated with serous OC, which accounts for 
the majority of clinical OC cases.  However, CA125 is not a useful screening 
marker due to high instances of false-positives and false-negatives.  Many 
factors can influence CA125 levels, including presence of other cancers, benign 
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disease, age, menses, hysterectomy, smoking history, race/ethnicity, and obesity 
[7, 35, 36].  Significant progress has been made in identifying potential 
biomarkers for the early detection of OC with the use of mass spectrometric 
protein profiling and other novel technologies.  Currently, mathematical 
techniques are being developed to analyze combinations of marker levels in an 
attempt to improve sensitivity and specificity. 
 
B-cell Lymphoma 2 
The B-cell lymphoma 2 (Bcl-2) gene was originally coined in 1986 as the 
oncogene product associated with the translocation t(14;18) [37, 38].   As a result 
of the translocation t(14;18), the Bcl-2 gene at chromosome segment 18q21 is 
juxtaposed with the immunoglobulin heavy chain locus at 14q32.  This 
translocation was originally discovered in a number of follicular lymphomas and 
resulted in deregulated expression of Bcl-2.  The anti-apoptotic effect of Bcl-2 
was established when its overexpression was shown to promote survival in 
interleukin-3-dependent cells in the absence of the cytokine [39].  The cloning of 
Bcl-2 homologous proteins Bax (Bcl-2-associated X) [40] and Bcl-x [41] in 1993 
lead to the discovery of a family of Bcl-2-like proteins which did not always play 
an anti-apoptotic role in cell survival.   
 
The Bcl-2 Family 
All Bcl-2 family members are made up of one or more of the four Bcl-2 
homology (BH) domains (Figure 1).  Each BH domain has a unique function [42]:   
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Figure 1.  Bcl-2 family members are made up of one or more Bcl-2 
homology (BH) domains.  The BH domains serve different functions:  BH1 and 
BH2 are for death suppression and pore formation, BH3 has death-promoting 
activity, BH4 has death repressor activity.  Most Bcl-2 family members also have 
a c-terminal transmembrane (TM) domain, which targets them to the outer 
mitochondrial, endoplasmic reticulum, or outer nuclear envelope membrane.
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BH1 and BH2 are responsible for death suppression (by binding to death agonist 
Bcl-2 family members) and pore formation; BH3 has death-promoting activity; 
BH4 has death repressor activity.  Most Bcl-2 family members also have a C-
terminal transmembrane domain, which targets them primarily to the outer 
mitochondrial membrane, endoplasmic reticulum (ER) membrane, and the outer 
nuclear envelope [43, 44].  Anti-apoptotic Bcl-2 proteins contain all four BH 
domains and include the Bcl-2-related A1 (Bcl-2A1), Bcl-2, Bcl-2-related gene, 
long isoform (Bcl-XL), myeloid cell leukemia 1 (Mcl-1), and Bcl-2-Like-2 (Bcl2l2) 
protein which is also known as Bcl-w. These members preserve the integrity of 
the outer mitochondrial membrane by forming heterodimers with their pro-
apoptotic counterparts, thus directly inhibiting their activity.  The pro-apoptotic 
Bcl-2 family members are divided into subfamilies of effectors and BH3-only 
proteins.  The effector pro-apoptotic proteins include Bcl-2 antagonist killer 1 
(Bak) and Bcl-2-associated x protein (Bax).  Like the anti-apoptotic proteins, they 
include all four BH domains.  When activated, these proteins homodimerize and 
permeabilize the outer mitochondrial membrane, resulting in release of 
cytochrome c, and ultimately, apoptosis.  BH3-only proteins are further 
subdivided based on their ability to interact with only anti-apoptotic family 
members or both the anti-apoptotic proteins and the effectors.  BH3-only 
members that only bind apoptotic family members are referred to as “sensitizer” 
or “derepressor” BH3-only proteins and include the Bcl-2 antagonist of cell death 
(Bad) and Noxa proteins.  These BH3-only proteins are able to form 
heterodimers with anti-apoptotic members, thus antagonizing their survival 
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function; however, these proteins are incapable of promoting cell death 
autonomously [42].  The BH3-only proteins, Bcl-2 interacting domain death 
agonist (Bid) and Bcl-2-interacting mediator of cell death (Bim), are capable of 
interacting with both the anti-apoptotic and effector Bcl-2 family members.  They 
can directly induce Bak and Bad oligomerization and permeabilization of the 
outer mitochondrial membrane.  These BH3-only proteins are called “direct 
activators”.  The Bcl-2 family members all work collectively to regulate the 
process of apoptosis. 
 
Bcl-2 and Apoptosis 
Apoptosis evasion is a key hallmark of cancer [45].  Apoptosis is the 
strategic and neat process by which a cell commits suicide.  It is much tidier than 
necrotic cell death which causes swelling and rupture of cells, leading to 
inflammation in surrounding tissue.  On the other hand, the apoptotic process 
involves three orderly phases:  the induction phase, the commitment/execution 
phase, and the degradation phase.  The induction phase begins when the cell 
receives a death stimulus such as physical damage, exposure to chemotoxins, or 
growth-factor withdrawal.  The commitment/execution phase of apoptosis 
signaling involves decreased cell volume with membrane blebbing and chromatin 
condensation.  This reduces cells to shriveled corpses, which are then rapidly 
phagocytosed, signifying the degradation phase.  Apoptosis is essential in 
controlling cell number, removal of aged, autoimmune, or damaged cells, and 
differentiation.  The formation of many types of malignant tumors involves 
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alteration of apoptotic regulation.  The culprit is often overexpression of anti-
apoptotic proteins, resulting in a decrease in apoptosis, and, therefore, 
uncontrolled cell proliferation [46-48].  The Bcl-2 family of proteins plays a central 
role in the promotion and suppression of apoptosis, acting primarily at the 
execution phase.  This extensive family of proteins regulates cytochrome c 
release from the mitochondria by decreasing (anti-apoptotic members, i.e. Bcl-XL, 
Bcl-2) or increasing (pro-apoptotic members, i.e. Bax, Bad, Bim) its permeability 
transition.  Cytochrome c release from the mitochondria results in a cascade of 
caspase activations and, ultimately, apoptosis.   
 
Bcl-2 and OC 
Bcl-2 has been established as a unique oncogene which prevents 
programmed cell death and does not play a role in promoting proliferation [49].  
Much evidence shows that Bcl-2 is localized to the mitochondrial outer 
membrane, though it has also been found to be present in the smooth ER as well 
as the perinuclear membrane.  Its anti-apoptotic property has been attributed to 
its ability to inhibit release of cytochrome c from the mitochondria, thus inhibiting 
downstream activation of caspases and ultimately apoptosis.  Overexpression of 
wildtype Bcl-2 has been reported to contribute to neoplastic transformation 
through inhibition of apoptosis [48].  Additionally, Bcl-2 overexpression in OC has 
been associated with chemoresistance.  Bcl-2 is associated with a favorable 
prognosis in non-small cell lung cancer [50], colorectal cancer [51], and breast 
cancer [52], whereas it is associated with poor prognosis in acute myeloid 
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leukemia [53], large B-cell lymphoma [54], and prostate cancer [55].  Several 
studies have found that EOC tissues [48, 56-60] as well as OC cell lines [57] 
express considerable amounts of the proto-oncogene Bcl-2, however, its 
prognostic significance in OC remains controversial.  Though upregulation of Bcl-
2 in OC has been identified, the molecular mechanisms regulating Bcl-2 
overexpression as well as potential extra-apoptotic consequences of Bcl-2 
overexpression remain unknown.   
The most commonly used chemotherapeutic treatment in OC patients is a 
combination of platinum (i.e. cisplatin, carboplatin) and taxane drugs (i.e. 
paclitaxel, docetaxel) [61].  The ability of OC to develop resistance to these 
drugs, especially platinum drugs, is a major dilemma to both patients and their 
physicians.  Though there have been a number of studies performed to see if 
Bcl-2 expression has an effect on OC resistance to platinum-based 
chemotherapy, the results have not been consistent [58]. 
 
Lysophosphatidic Acid 
Lysophosphatidic acid (LPA; 1-acyl-2-hydroxy[lyso]-sn-glycero-3-
phosphate) is the simplest glycerophospholipid and has been shown to have an 
extensive range of biological activities.  There are currently eight known LPA-
responsive G protein-coupled receptors (GPCR).  LPA activates receptors in the 
G protein-coupled family of receptors encoded by the endothelial differentiation 
genes (EDG), specifically, LPA1/EDG2, LPA2/EDG4, and LPA3/EDG7 [62-68] 
(Figure 2).  More recent studies have shown that LPA also activates receptors  
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Figure 2.  LPA binds to EDG family receptors EDG2, EDG4, and EDG7, 
which are coupled to G-proteins, and activates multiple downstream 
effector pathways.  Gi and Gq activate PLC, resulting in generation of 
diacylglycerol (DAG) and inositol triphosphate (IP3).  DAG activates protein 
kinase C (PKC), and IP3 mobilizes intracellular calcium ([Ca2+]i).  Gi inhibits 
adenylyl cyclase (AC) and thus cyclic adenosine monophosphate (cAMP). 
Alternatively, Gi activates the Ras/mitogen-activated protein kinase (MAPK) 
pathway.  Gi also activates phosphoinositide 3-kinase (PI3K), which activates Akt 
and Rac.  Activation of Rho by G12/13 leads to subsequent activation of serum 
response factor (SRF) and Rho-associated kinase (ROCK).
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LPA4/p2y9/GPR23, LPA5/GPR92, LPA6/GPR87, LPA7/p2y5, and LPA8/p2y10 in 
the purinergic receptor cluster of GPCR [69-72], which are structurally distinct 
from the EDG receptors. 
 
EDG Family LPA Receptors 
EDG receptors have been shown to exert their effects by coupling to the G 
proteins Gi/o, G12/13, and Gq.  Under physiological conditions the EDG receptors 
have not been shown to couple to Gs.  LPA stimulation leads to EDG2 coupling 
to mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 
(ERK), resulting in cell proliferation [73].  This effect is blocked by pertussis toxin 
(PTX), a Gi/o inhibitor, indicating that Gi/o mediates this response.  Stimulation of 
EDG2 also causes Gi/o-mediated inhibition of adenylyl cyclase (AC) [62, 74, 75]  
Additionally, EDG2 causes Gq-mediated phospholipase C (PLC) activation, which 
is PTX-insensitive and G12/13-mediated Rho activation, which can be inhibited by 
botulinum C3 toxin [76-78].  Activation of the Rho-dependent signal cascade 
results in cell rounding and neurite retraction in neuronal cells and stress fiber 
formation in fibroblasts, contributing to LPA’s ability to cause changes in cell 
morphology [62, 77].  EDG4 and EDG7 receptors have signaling properties 
similar to EDG2, however, EDG7 is not coupled to the Rho pathway, whereas 
this is not the case for EDG2 and EDG4 receptors [78].  Lastly, EDG4 and EGD7 
receptors also couple to Gq, resulting in mobilization of intracellular Ca2+ [66, 67, 
75].   
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The EDG family LPA receptors have been found to be differentially 
expressed according to tissue type.  EDG2 is expressed in almost all tissues with 
the greatest abundance in organs including the brain, ovary, and heart and the 
lowest abundance in the liver, lung, peripheral blood leukocytes, and thymus 
[66].  EDG4 is expressed greatest in peripheral blood leukocytes and testes with 
less expression in pancreas, spleen, thymus, and prostate.  However, in tissues 
were EDG2 is expressed abundantly:  brain, heart, placenta, ovary, and digestive 
tract, EDG4 is virtually undetectable [66].  EDG7 expression is most abundant in 
prostate, testes, pancreas, and heart, with moderate expression in the lung and 
ovary [67].  EDG7 is undetectable in other tissues. 
 
Non-EDG Family LPA Receptors 
Several human GPCRs have recently been de-orphanized, resulting in the 
discovery of a group of LPA receptors closely related to the purinergic P2Y 
receptors.  LPA4/p2y9/GPR23 was found when Chinese hamster ovary cells 
stably transfected with orphan GPCRs were screened with 198 lipids.  
LPA4/p2y9/GPR23 was able to be activated by 1-oleoyl-LPA-mediated coupling 
to Gs, leading to induction of intracellular Ca2+ mobilization and cyclic adenosine 
monophosphate (cAMP) formation [79].  Stimulation of cAMP formation via LPA4 
was later found to be cell-type dependent [80]. Further studies showed that 
stimulation of LPA4 led to phenomena similar to what happens with EDG receptor 
activation, such as neurite retraction and cell aggregation as well as an anti-
migratory effect that seems to involve activation of Rho through G12/13 [80-83].  
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LPA5/GPR92 was identified when its expression lead to G12/13 and Rho-mediated 
neurite retraction, receptor internalization, increased [3H]-LPA binding to 
membrane fractions, increased cAMP accumulation, and intracellular Ca2+ 
mobilization via Gq in both rat neuroblastoma and hepatoma cells [84].  De-
orphanization of the LPA7/p2y5 receptor divulged its involvement in the 
regulation of hair follicle development and hair growth [70, 85].  LPA stimulation 
also revealed cAMP response element driven transcription in cells stably and 
transiently expressing LPA7.  LPA6/GPR87 and LPA8/p2y10 have also been 
suggested to be LPA receptors [71, 72], however, because the cell types used in 
the studies had intrinsic responses to LPA, further studies are suggested using 
cell lines that are hyposensitive to LPA to confirm that these receptors have not 
been misidentified [86]. 
 
Biological Functions of LPA 
LPA production in multiple cell types, including OC cell lines, has been 
reported.  LPA has several pleiotropic biological functions in a number of cell 
types. Some roles of LPA include mediation in wound healing and tissue 
regeneration, stimulation of cell proliferation, cell survival, platelet aggregation, 
and tumor cell invasion.  LPA plays a role in embryonic development of the 
nervous system.  Stimulation of EDG2 by LPA in oligodendrocytes and Schwann 
cells protects these cells from apoptosis through activation of the 
phosphatidylinositol 3-kinase (PI3K) /Akt cell survival signal pathway.  LPA is 
able to induce cell cycle-dependent morphological changes and cell migration via 
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EDG2 stimulation in cortical neuroblasts in vitro (reviewed in [78]).  LPA-
mediated EDG4 activation is suspected to modulate neurite formation and control 
migration of post-mitotic differentiating neurons to their final destination.  
Furthermore, LPA has been shown to mediate neuronal cell MAPK activation and 
arachidonic acid release via all three EDG receptors [75].   
LPA is elevated in both the plasma and ascites fluid of OC patients [87-89] 
and has been proposed as a diagnostic tool for OC [89].  EDG2 expression is 
exceptionally high in slowly proliferating and cisplatin-resistant cell lines, whereas 
it is virtually absent from rapidly proliferating and cisplatin-sensitive OC cell lines.  
Therefore, it has been suggested that this LPA receptor plays a role in negative 
regulation of ovarian epithelial cell growth and metastasis [90].  OC cell lines 
secrete considerable amounts of LPA into their culture medium which can further 
stimulate LPA production in an autocrine fashion via EDG4 and EDG7 receptors.  
These receptors are overexpressed in OC cells in comparison to normal and 
even immortalized ovarian surface epithelial cells [91, 92].  LPA activation of 
EDG7 is proposed to be related to OC cell growth [92, 93] and proliferation [92].  
This is supported by evidence confirming significantly higher expression of EDG7 
in immature teratoma, endometrioid adenocarcinoma, and serous 
cystadenocarcinoma tissues compared to normal ovarian tissue [94].  However, 
there are no significant differences in EDG7 expression among clear cell 
adenocarcinoma, mucinous cystadenocarcinoma, and undifferentiated 
adenocarcinoma tissue when compared to its expression in normal ovarian 
tissue.  In addition to its role in cell proliferation, LPA has also been shown to 
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elicit anti-apoptotic activity through upregulation of Bcl-2 at both mRNA and 
protein levels in intestinal epithelial cells [95].  It is likely that LPA-mediated Bcl-2 
upregulation occurs in OC because the ascites fluid of OC patients is rich in LPA 
[87, 88] and ovarian tumors also overexpress Bcl-2 [48, 56-60].  
 
Angiogenesis 
Angiogenesis is the formation of new blood vessels from preexisting 
vasculature.  Tumor vascularization plays a vital part in OC progression and 
prognosis given that ovarian carcinomas are often associated with multifocal 
intraperitoneal spreading along with profound neovascularization.   
 
Vascular Endothelial Growth Factor 
The first angiogenic factor was postulated in 1970 when Folkman 
discovered a soluble protein that was secreted from both human and animal solid 
tumors which had a mitogenic effect on capillary endothelial cells [96].  He and 
his colleagues termed this protein tumor angiogenesis factor (TAF) and 
suggested that it could be blocked to arrest the growth of solid tumors.  TAF was 
later identified as Basic Fibroblast Growth Factor (bFGF), a growth factor which 
stimulated the growth of several cell types, including endothelial cells, and whose 
angiogenic properties had already been recognized [97].  Later, one of the most 
potent and most studied angiogenic factors, vascular endothelial growth factor 
(VEGF), was identified when Senger et al. discovered its presence in the culture 
supernatant and ascites of rodent tumors [98].  The VEGF-related gene family 
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consists of six secreted glycoproteins referred to as VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E and placental growth factors-1 and -2 [99].  VEGF-A the 
prototype family member, is often referred to as VEGF.  Alternative splicing of the 
VEGF gene results in four mature isoforms containing 121, 165, 189, and 206 
amino acids [100, 101].  The 165 amino acid isoform is most commonly 
expressed in both normal and tumor cells.  VEGF is a key regulator of blood 
vessel growth and was originally given the name vascular permeability factor 
(VPF) due to its ability to increase microvascular permeability to circulating 
macromolecules [98, 102, 103].  VEGF has been shown to play a role in 
endothelial cell proliferation and modeling of the vessel wall in both normal and 
abnormal circumstances [99, 104].   
 
Mechanisms of Angiogenesis 
Angiogenesis is a highly regulated multi-step process.  It begins with 
vasodilation and VEGF-mediated vascular permeabilization, which allows 
extravasation of plasma proteins which deposit a temporary scaffold for migrating 
endothelial cells (reviewed in[105]).  Angiopoietin (Ang) 2 (an inhibitor of Tie2 
signaling) and various proteinases facilitate detachment of smooth muscle cells 
and degradation of the extracellular matrix, respectively, contributing to 
destabilization of mature blood vessels, a process required for the release and 
migration of endothelial cells [105].  Several molecules, including tumor necrosis 
factor α, transforming growth factor (TGF) β1, members of the chemokine system 
and the platelet-derived growth factor, FGF, and VEFG families, stimulate the 
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migration and proliferation of endothelial cells.  Once endothelial cells assemble 
as a solid cord, they eventually acquire a lumen, which is dependent on VEGF 
family members, Ang1, integrins (αvβ3 or αvβ5) and the myocyte enhancer binding 
factor 2C [105].  Ang1, a ligand of the endothelial Tie2 receptor, is a natural 
inhibitor of vascular permeability and tightens preexisting blood vessels, hence, it 
plays a role in vessel maturation.  Upon assemblage of vessels, endothelial cells 
undergo differentiation and remodeling.  Maturation of the vascular network into a 
system with larger and smaller vessels involves ‘pruning’ and remodeling of 
capillary-like tubules with uniform size, and irregular organization into a 
structured network of branching vessels [105].  Excess endothelial cells are lost 
during the remodeling process [106].  Though the molecular mechanisms of 
remodeling remain to be elucidated, it has recently been suggested that cell loss 
during remodeling is due to apoptosis and is critical to proper remodeling of 
endothelial cells and tube formation in vivo [107]. 
Besides the above-mentioned mechanism, which is classically referred to 
as sprouting angiogenesis, alternate angiogenic mechanisms have been 
described in tumors, namely vessel co-option and vasculogenic mimicry.  Vessel 
co-option occurs when vascular supply is inadequate for a cell population, 
resulting in migration and relocation of the tumor cells to a preexisting capillary 
[108].  Pro-angiogenic factors are secreted under hypoxic conditions, stimulating 
the proliferation and migration of endothelial cells from nearby vessels to begin 
neovascularization.  Vascular mimicry is a more recent and highly debated 
phenomenon whereby a collection of multipotential cancer cells differentiates into 
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endothelial cell-mimics, which line the vascular channels, as opposed to 
endothelial cells [109-111].   
Regardless of their route of formation, tumor blood vessels differ 
tremendously from their normal counterparts.  They typically possess abnormal 
branching patterns, irregular diameters, corkscrew structures, and blind ends and 
can, therefore, not be classified as arterioles, capillaries, or venules [112].  
Tumor vessels also display avid binding and uptake of cationic liposomes, and 
expression of integrins, growth factors, and receptors that vary from those of 
normal vessels [106, 108, 113].  Unusual leakiness of nascent vessels also 
distinguishes them from normal vasculature and aids the process of metastasis.  
The fenestrated basement membranes of tumor vessels allows increased 
accessibility to stray tumor cells [114].  Though more work needs to be done, 
studies on vessel permeability have proven to be key in the advancement of 
chemotherapy delivery and improving anti-angiogenic therapies.  
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CENTRAL HYPOTHESIS 
 
Bcl-2 has been shown to be elevated in a number of solid tumors, including OCs.  
Though upregulation of Bcl-2 in OC has been identified, detailed information on 
the molecular mechanisms responsible for Bcl-2 upregulation and the potential 
for non-anti-apoptotic Bcl-2-dependent activities remains unclear.  LPA is also 
overexpressed in ovarian tumors and has been shown to upregulate Bcl-2 in 
other epithelial tissues.  I hypothesize that LPA, in part, drives the production and 
secretion of Bcl-2 in OC cells and that extracellular Bcl-2 has novel effects on 
ovarian tumors outside of its known anti-apoptotic activity. 
 
 
SPECIFIC AIMS 
 
1. Confirm the clinical correlation between Bcl-2 and OC progression. 
 
2. Confirm that LPA, in part, drives the production and secretion of Bcl-2 in OC 
and determine the biological significance of elevated Bcl-2 in OC by 
evaluating the role that extracellular Bcl-2 plays in angiogenesis. 
 
3. Demonstrate that Bcl-2 may be used as a diagnostic tool in OC by evaluating 
urinary Bcl-2 levels of OC patients, women with benign gynecologic disease, 
and normal healthy volunteers. 
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CHAPTER II: 
BCL-2 EXPRESSION IS ALTERED WITH OVARIAN TUMOR PROGRESSION:  
AN IMMUNOHISTOCHEMICAL EVALUATION 
 
Abstract 
OC is the most lethal gynecologic malignancy.  The ovarian tumor 
microenvironment is comprised of tumor cells, surrounding stroma, and 
circulating lymphocytes, an important component of the immune response, in 
tumors.  Previous reports have shown that the anti-apoptotic protein Bcl-2 is 
overexpressed in many solid neoplasms, including OCs, and contributes to 
neoplastic transformation and drug-resistant disease, resulting in poor clinical 
outcome.  Likewise, studies indicate improved clinical outcome with increased 
presence of lymphocytes. Therefore, I sought to examine Bcl-2 expression in 
normal, benign, and cancerous ovarian tissues to determine the potential 
relationship between epithelial and stromal Bcl-2 expression in conjunction with 
the presence of lymphocytes for epithelial ovarian tumor progression.  Ovarian 
tissue sections were classified as normal (n=2), benign (n=17) or cancerous 
(n=28) and immunohistochemically stained for Bcl-2.  Bcl-2 expression was 
assessed according to cellular localization, extent, and intensity of staining. The 
number of lymphocyte nests as well as the number of lymphocytes within these 
nests was counted.  While Bcl-2 staining remained cytoplasmic, both percent and 
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intensity of epithelial and stromal Bcl-2 staining decreased with tumor 
progression.  Further, the number of lymphocyte nests dramatically increased 
with tumor progression.  The data suggest alterations in Bcl-2 expression and 
lymphocyte infiltration correlate with epithelial OC progression.  Consequently, 
Bcl-2 expression and lymphocyte status may be important for prognostic 
outcome or useful targets for therapeutic intervention. 
 
Introduction 
OC currently ranks 5th in cancer related deaths among women in the 
United States[1]  in spite of advances in treatment.  Despite an overall OC 
survival rate of 45%, the five year survival rate for women diagnosed with OC in 
its early stages is 94%, however these women only make up 19% of reported OC 
cases [7].  This poor prognosis is, in part, due to a lack of symptoms at early 
stages as well as lack of a screening marker available to the general public.  The 
OSE is generally believed to be the origin for the majority of epithelial OC cases 
[115], though current reports of a fallopian tube origin for OC have emerged [15, 
19].  Consequently, the etiology of OC is still poorly understood. 
A basement membrane consisting mainly of collagenous connective tissue 
separates the OSE, a modified mesothelium, from underlying ovarian stromal 
tissue [116].  The OSE and stroma both synthesize and secrete components that 
contribute to deposition of the basement membrane during postovulatory repair 
[117].  Normal ovarian stroma also produces an array of growth factors, 
including, but not limited to TGF-β1 and the hepatocyte growth factor (HGF) 
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receptor c-Met that stimulate autocrine and paracrine-mediated proliferation of 
the superjacent epithelium.  These growth factors tend to be overexpressed in 
many carcinomas, hence facilitating neoplastic growth [118].  Additionally, 
stromal-epithelial interactions have been studied in cancers of the bladder, 
breast, cervix, colon, prostate, and ovary [119-124] and have shown that stromal 
cells influence epithelial cell growth as well as tumorigenesis. 
In addition to the role of the tumor microenvironment, alterations in 
apoptotic regulation promoting an anti-apoptotic phenotype also support tumor 
progression. Specifically, Bcl-2, recognized as the prototypical anti-apoptotic 
protein, is overexpressed in a number of solid tumors, including OC, and 
contributes to neoplastic transformation through inhibition of apoptosis [48], 
thereby promoting tumor survival.  
In contrast, ovarian tumors can also elicit a marked host immune response 
resulting in the influx of tumor infiltrating lymphocytes into the tumor which 
recognize antigens expressed on ovarian tumors [125]. The presence of tumor 
infiltrating lymphocytes in OC patients appears to confer a survival advantage 
[126-128]; however, this immune response is not normally sufficient to inhibit 
tumor growth over extended periods of time.  
While several studies have previously examined Bcl-2 or the contribution 
of tumor infiltrating lymphocytes separately for OC prognosis, I sought to further 
determine the combined clinical relationship between Bcl-2 expression and 
lymphocyte filtration for OC progression.  To my knowledge, there have not been 
any other similar studies to date.  Therefore, given the close proximity of tumor 
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cells, their surrounding stroma, and infiltrating lymphocytes, I analyzed the 
immunohistochemical expression and histological localization of Bcl-2 in ovarian 
the stromal and epithelial components of normal, benign, and cancer clinical 
specimens as well as evaluated changes in lymphocyte populations with ovarian 
tumor progression. 
 
Materials and Methods 
 
Tissue Specimens 
With institutional approval, a previously existing tissue bank was utilized to 
retrieve a cohort of de-identified women who had undergone primary surgery with 
complete surgical staging for EOC or borderline tumors at the H. Lee Moffitt 
Cancer Center between 2000 and 2001.  This gynecologic oncology procedure 
database was also used to select women who had undergone oophrectomy due 
to cystadenoma or had their ovaries removed for unrelated pathology between 
2000 and 2001.  All tissue specimens were fixed with 10% formalin and paraffin-
embedded.  Four micron sections were stained with haematoxylin and eosin (H & 
E) and the slides were reviewed by a pathologist (SVN) to confirm histologic 
diagnosis according to the FIGO classification system.  The de-identified medical 
records of these women were reviewed, and tumor pathology was correlated to 
the immunohistochemical findings.  From these observations, the selected 
ovarian sections were given the following classifications:  2 normal, 17 benign 
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cysts or cystadenomas, and 28 serous papillary carcinomas, though areas of 
normal OSE were also present in 5 benign and 4 carcinoma sections. 
 
Immunohistochemistry 
For immunohistochemical studies, further formalin-fixed paraffin sections 
were cut at 3 microns and dried overnight at room temperature then 
deparaffinized and rehydrated.  Sections were soaked in hydrogen peroxide to 
block endogenous peroxidase activity.  Microwave antigen retrieval was achieved 
by placing slides in 1X solution of AR-10 (BioGenex #HK057-5K, San Ramon, 
CA), boiling, and then microwaving for an additional 10 minutes.  The specimens 
were then immunostained on the Dako Autostainer (Dako North America, Inc., 
Carpinteria, CA) using Monoclonal Mouse Anti-Human Bcl-2 (Clone 124, Dako, 
Carpinteria, CA) primary antibody (1:40) for 30 minutes and the Dako’s 
EnVision™ + horse radish peroxidase (HRP) Mouse (DAB+) kit according to the 
manufacturer’s instructions, then counterstained with modified Mayer’s 
haematoxylin, dehydrated through graded alcohol, cleared with xylene, and 
mounted with resinous mounting medium.  In an effort to control variability, all 
samples were stained at the same time and with the same lot of reagents.  
Normal tonsil was used as an internal positive control while negative controls 
were obtained by substitution of primary antibody with normal mouse serum.   
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Staining Analysis 
Immunohistochemical staining was evaluated independently by four 
individuals (LP, NSA, PAK, and SVN).  The pattern of Bcl-2 staining was 
evaluated as nuclear or cytoplasmic.  Amount of stromal and epithelial staining 
was assessed as percent staining from each section and scored as having either 
≤50% or >50% positive cells.  Staining intensity was also evaluated and 
classified as negative, weak, moderate, or intense staining.  The presence of 
lymphocyte nests in each section was also observed and counted by observing 
assemblages of ten or more lymphocytes in 10 random viewings at a total 
magnification of 100X.  The number of lymphocytes in each observed nest was 
also counted and grouped into 5 categories:  <25, 25-50, 50-75, 75-100, or >100 
lymphocytes per nest. 
 
Statistical Analysis 
SAS version 9.2 (SAS Institute, Cary, NC) was used for statistical analysis 
of Bcl-2 staining in normal, benign, and cancerous tissue samples.  Fisher’s 
exact test was used to test for associations in extent of epithelial and stromal 
staining between tumor types and staining intensity of epithelial and stromal 
staining between tissue types.  The Cochran–Mantel–Haenszel test was used to 
test for independence between tissue type and lymphocyte nest size.  The 
generalized linear model, along with pair-wise comparison among tissue types 
was used to test for differences in tissue type and the number of lymphocyte 
nests present. 
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Results 
Immunohistochemical staining was performed on a total of 47 ovarian 
tissue sections as characterized in table 1.  The mean age of the sample 
population was 62 years (range, 33-88 years) and no significant differences were 
noted in age among categories.  The predominant histologic type for malignant 
tissue samples was serous (26/28), and patients typically presented with high 
grade tumors (Grade 3, 19/28).  The majority of the malignant samples were also 
from patients with stage III OC (25/28).  Samples classified as “other” included 
follicular cysts and a cystadenofibroma. 
 
Epithelial Bcl-2 Staining Decreases with OC Progression 
All tissues in this study, with the exception of four poorly differentiated 
serous papillary carcinomas, displayed some degree of epithelial and/or stromal 
Bcl-2 staining.  Bcl-2 staining was confined to the cytoplasm in epithelial and 
stromal cells.  While only 2 specimens were classified as normal, there were 
areas of normal epithelia on 5 benign and 4 cancerous specimens.  Due to the 
small number of normal specimens procured, I included these additional areas in 
normal epithelial analyses.  Epithelial Bcl-2 staining was present in 91% (10/11) 
normal, 100% (17/17) benign, and 79% (22/28) cancer specimens (Figure 3, 
Table 2).  Further, 65% (11/17) benign specimens showed epithelial Bcl-2 
staining in more than 50% of their epithelial cells, whereas, 18% (2/11) and 29% 
(8/28) normal and OC tissues, respectively, displayed epithelial Bcl-2 staining to 
the same extent (Table 2).  In the cancerous sections, extent of Bcl-2 epithelial 
32 
 
TABLE 1.  Characteristics of the study cohort. 
 
 
 
 
Normal 
(n=2) 
 
Cysts 
(n=4) 
 
Cystadenomas 
(n=13) 
 
WD (Grade 1) 
(n=3) 
 
MD (Grade 2) 
(n=6) 
 
PD (Grade 3) 
(n=19) 
 
 
Age (years) 
    Mean (SD) 
    Range 
 
 
 
57.5 (12.0) 
49-66 
 
 
 
58.0 (16.1) 
48-81 
 
 
 
65.0 (10.1) 
49-79 
 
 
 
48.7 (6.5) 
42-55 
 
 
 
64.8 (16.7) 
33-76 
 
 
62.7 (14.5) 
33-88 
 
Histology 
    Serous 
    Mucinous 
    Endometrioid 
    Other 
 
 
 
N/A 
N/A 
N/A 
N/A 
 
 
1 
0 
0 
3 
 
 
11 
1 
0 
1 
 
 
1 
0 
2 
0 
 
 
6 
0 
0 
0 
 
 
19 
0 
0 
0 
Stage 
    I 
    II 
    III 
    IV 
 
N/A 
N/A 
N/A 
N/A 
 
N/A 
N/A 
N/A 
N/A 
 
N/A 
N/A 
N/A 
N/A 
 
0 
1 
2 
0 
 
0 
0 
6 
0 
 
1 
0 
17 
1 
 
N/A indicates category was not applicable to those samples. 
WD = well differentiated carcinoma, MD = moderately differentiated serous papillary carcinoma, PD = poorly differentiated 
serous papillary carcinoma
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Figure 3.  Bcl-2 staining is more extensive in cysts than normal and cancerous sections.  Positive Bcl-2 staining in 
epithelial cells of normal (A), follicular cyst (B), and moderately differentiated serous papillary carcinoma (C) sections.  
(Original magnification:  200X).
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TABLE 2.  Bcl-2 immunoreactivity in ovarian tissue sections. 
 
__% Positive Epithelium (n)__ 
 
___% Positive Stroma (n)___ 
 
 
 
 
Total 
Total ≤ 50% > 50% Total ≤ 50% > 50% 
 
       
Normal 
Normal within Benign 
Normal within Cancer 
Total Normal 
2 
5 
4 
11 
50 (1) 
100 (5) 
100 (4) 
91 (10) 
100 (2) 
100 (5) 
50 (2) 
82 (9) 
0 
0 
50 (2) 
18 (2) 
100 (2) 
— 
— 
100 (2) 
0 
— 
— 
0 
100 (2) 
— 
— 
100 (2) 
Cysts 
Cystadenomas 
Total Benign 
4 
13 
17 
100 (4) 
100 (13) 
100 (17) 
25 (1) 
38 (5) 
35 (6) 
75 (3) 
62 (8) 
65 (11) 
50 (2) 
92 (12) 
82 (14) 
75 (3) 
62 (8) 
65 (11) 
25 (1) 
38 (5) 
35 (6) 
WD 
MD 
PD 
Total Cancerous 
3 
6 
19 
28 
100 (3) 
100 (6) 
68 (13) 
79 (22) 
33 (1) 
67 (4) 
79 (15) 
71 (20) 
67 (2) 
33 (2) 
21 (4) 
29 (8) 
100 (3) 
17 (1) 
68 (13) 
61 (17) 
66 (2) 
83 (5) 
95 (18) 
89 (25) 
33 (1) 
17 (1) 
5 (1) 
11 (3) 
 
 
WD = well differentiated carcinoma, MD = moderately differentiated serous papillary carcinoma, PD = poorly differentiated 
serous papillary carcinoma 
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staining tended to decrease with increased tumor grade (Table 2, Figure 4).  
More than 50% of the epithelial cells stained positive for Bcl-2 in 67% (2/3) of 
well differentiated carcinomas (WD), 33% (2/6) of moderately differentiated 
serous papillary carcinomas (MD), and 21% (4/19) of poorly differentiated serous 
papillary carcinomas (PD) (Table 2, Figure 4).  Though there was a trend, these 
differences were not statistically significant.  Similar to the extent of staining, 
intensity of epithelial Bcl-2 staining was higher in benign samples, with 94% 
(16/17) of benign sections showing an intensity of moderate or intense, while 
64% (7/11) and 43% (12/28) normal and malignant sections, respectively, 
showed an epithelial staining intensity of moderate or intense degree (Figure 5).  
More specifically, the epithelial staining intensity in cystadenomas was 
significantly higher than that in both MD and PD sections (P=0.02 and P<0.0001, 
respectively), but not in WD sections.  Comparison among the cancerous 
samples showed that there was decreased epithelial Bcl-2 intensity with 
advanced tumor grade (Figure 5); however, these differences did not reach 
statistical significance.  
 
Stromal Bcl-2 Staining Decreases with OC Progression 
Like epithelial staining, stromal Bcl-2 staining also decreased with 
malignant progression (Figure 6).  One hundred percent (2/2) normal, 82% 
(14/17) benign, and 61% (17/28) malignant samples stained positive for stromal 
Bcl-2 (Table 2).  While 100% (2/2) of the normal specimens were found to have a 
positive Bcl-2 staining in more than 50% of the stromal cells, 35% (6/17) of  
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Figure 4.  Extent of epithelial Bcl-2 staining in ovarian tissues.  Extent of 
epithelial Bcl-2 staining was observed wholly in each section of normal (N), cyst 
(Cy), cystadenoma (CyAd), well-differentiated serous papillary carcinoma (WD), 
moderately-differentiated serous papillary carcinoma (MD), and poorly-
differentiated serous papillary carcinoma (PD) ovarian tissue and categorized as 
either: ≤50% or >50% positive staining.  Scored sections were graphed as a 
percent according to total sections of each tumor type. 
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Figure 5.  Intensity of epithelial Bcl-2 staining decreases with tumor 
progression.  Intensity of epithelial Bcl-2 staining was observed wholly in each 
section of normal (N), cyst (Cy), cystadenoma (CyAd), well-differentiated serous 
papillary carcinoma (WD), moderately-differentiated serous papillary carcinoma 
(MD), and poorly-differentiated serous papillary carcinoma (PD) ovarian tissue 
and categorized as having negative, weak, moderate, or intense staining.  
Scored sections were then graphed as a percent according to total sections of 
each tumor type. 
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Figure 6.  Stromal Bcl-2 staining decreases with tumor progression.  Stromal Bcl-2 staining in normal (A), serous 
cystadenoma (B), and moderately differentiated serous papillary carcinoma (C) sections.  (Original Magnification: 40X) 
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benign tumors had Bcl-2 expression in more than 50% of the stromal cells 
(Figure 7).  In contrast, only 11% (3/28) of OC sections had more than 50% of 
their stromal cells expressing Bcl-2 (Figure 7).  Similar to extent of epithelial Bcl-2 
staining, differences in extent of stromal Bcl-2 staining between tumor types were 
not statistically significant, with the exception of PD samples having significantly 
less staining than both normal and cystadenoma samples (P=0.1 and 0.03, 
respectively).  Stromal intensity was moderate in 100% (2/2) of the normal 
tissues, and in 82% (14/17) benign tumors (Figure 8).  However, moderate 
stromal intensity decreased to 29% (8/28) in OC sections (Figure 8).  Stromal 
Bcl-2 intensity in cystadenomas was significantly different versus intensity in MD 
and PD specimens (P=0.003 and P<0.0001, respectively), while stromal Bcl-2 
intensity in cysts was not significantly different from any of the specimens.  
Likewise, stromal intensity decreased with increased tumor grade with 100% 
(3/3) WD, 17% (1/6) MD, and 21% (4/19) PD displaying moderate stromal 
intensity for Bcl-2 staining (Figure 8).  Additionally, PD stromal intensity was 
significantly lower than MD (P=0.05).    
 
Bcl-2-Positive Lymphocyte Nests Increase with OC Progression 
In contrast, the average number of lymphocyte nests (defined as 
aggregates of 10 or more lymphocytes) (Figure 9, Table 3) present per section 
increased with malignant progression.  While normal and benign samples both 
averaged less than two lymphocyte nests per section, WD sections averaged 
3.33 lymphocyte nests per section, and higher grades displayed significantly 
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Figure 7.  Extent of stromal Bcl-2 staining decreases with tumor 
progression.  Extent of stromal Bcl-2 staining was observed wholly in each 
section of normal (N), cyst (Cy), cystadenoma (CyAd), well-differentiated serous 
papillary carcinoma (WD), moderately-differentiated serous papillary carcinoma 
(MD), and poorly-differentiated serous papillary carcinoma (PD) ovarian tissue 
and categorized as either: 0% positive, <5% positive, 5-25% positive, 26-50% 
positive, 51-75% positive, or >76% positive staining.  Scored sections were 
graphed as a percent according to total sections of each tumor type. 
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Figure 8.  Intensity of stromal Bcl-2 staining in ovarian tissues.  Intensity of 
stromal Bcl-2 staining was observed wholly in each section of normal (N), cyst 
(Cy), cystadenoma (CyAd), well-differentiated serous papillary carcinoma (WD), 
moderately-differentiated serous papillary carcinoma (MD), and poorly-
differentiated serous papillary carcinoma (PD) ovarian tissue and categorized as 
having negative, weak, moderate, or intense staining.  Scored sections were then 
graphed as a percent according to total sections of each tumor type.  
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Figure 9.  Lymphocyte nests are more abundant in malignant sections.  Bcl-
2 staining in a representative photo of a large lymphocyte nest in a poorly 
differentiated serous papillary carcinoma tumor.  (Magnified 100X) 
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TABLE 3.  Lymphocyte nests and number of lymphocytes in each nest according to tissue type. 
     
# Lymphocytes in Nests Tumor Type n # Lymph 
Nests* <25 25-50 50-75 75-100 >100 
Average Lymph 
Nests/Section* 
         
Normal 2 0 0 0 0 0 0 0 
Benign 
    Cyst 
    Cystadenoma 
    Total 
 
4 
13 
17 
 
6 
13 
19 
 
1 
8 
9 
 
3 
1 
4 
 
2 
2 
4 
 
0 
1 
1 
 
0 
1 
1 
 
1.50 
1.00 
1.12 
Cancerous 
    WD 
    MD 
    PD 
    Total 
 
3 
6 
19 
28 
 
10 
46 
149 
205 
 
1 
11 
23 
35 
 
4 
11 
25 
40 
 
3 
9 
23 
35 
 
1 
2 
12 
15 
 
1 
13 
66 
80 
 
3.33 
7.67 
7.84 
7.32 
 
*Lymph Nests = aggregates of 10 or more lymphocytes 
WD = well differentiated carcinoma, MD = moderately differentiated serous papillary carcinoma, PD = poorly differentiated 
serous papillary carcinoma 
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more lymphocyte nests with MD (P=0.01) and PD (p=0.003) sections having 
averages of 7.67 and 7.84 lymphocyte nests per section, respectively.  Due to 
small sample sizes within tissue subtypes, the samples were divided simply into 
normal, benign, or cancerous to analyze differences in the sizes of lymphocyte 
nests (Table 3).  Interestingly, the size of lymphocyte nests also significantly 
increased as tumors became cancerous (p=0.004).  Additionally, lymphocyte 
population may also be associated with cancer stage because the stage I and II 
OC sections did not contain any lymphocyte nests and, with the exception of one 
stage III cancer specimen, the stage IV cancer specimen had the highest amount 
of nests that contained >100 lymphocytes (data not shown). 
 
Discussion 
While there have been several studies examining Bcl-2 expression with 
ovarian tumor progression or the prognostic importance of the presence of 
lymphocytes for clinical outcome in OC, this is the first study to examine Bcl-2 
expression in both epithelial and stromal cells as well as lymphocyte distribution 
with OC progression.  In agreement with previous studies [57, 129, 130], I found 
that over 50% of OCs stained for Bcl-2, but I also detected Bcl-2 staining in 
normal and benign ovarian specimens. Further, epithelial Bcl-2 staining was 
greater in normal and benign ovarian specimens compared with cancer 
specimens.  This is in agreement with other studies [56, 131, 132] which reported 
greater Bcl-2 expression in normal and benign specimen compared to cancer 
samples.  Chan et al. [56] proposed that decreased Bcl-2 expression with tumor 
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progression resulted from the dysregulation of Bcl-2 normally required to 
maintain physiological function and integrity of the normal OSE.  Similarly, other 
studies [56, 129, 133] have reported an inverse relationship between epithelial 
Bcl-2 expression and tumor grade.  For example, Baekelandt et al. [134] found 
only 39% of stage III epithelial ovarian carcinomas displayed immunoreactivity to 
Bcl-2 in more than 5% of the tumor cells.  They did not compare these levels to 
Bcl-2 expression in normal ovarian tissue, but they did conclude that Bcl-2 
expression was inversely related to tumor aggressiveness.  In the present study, 
57% (16/28) of the OC specimens showed positive Bcl-2 staining in more than 
5% of the tumor cells regardless of cancer stage.  However, when only stage III 
OC specimens were considered, 42% (8/19) of the samples demonstrated 
positive Bcl-2 staining in more than 5% of the tumor cells (data not shown) which 
is very similar to findings reported by Baekelandt et al [134].  Interestingly, we 
have recently reported increased levels of urinary Bcl-2 in OC patients ([135], 
Chapter 4) suggesting that reduced epithelial Bcl-2 staining with tumor 
progression may reflect a transition from cellular expression of Bcl-2 to secreted 
Bcl-2 associated with disease progression. 
Further, normal ovarian endocrine and reproductive function depends on a 
multifaceted and dynamic microenvironment that involves coordinated cell-cell 
interactions [136].  Likewise, stromal-epithelial interactions, as seen in breast 
carcinomas [137-139], play an important role in determining ovarian malignant 
progression.  This is supported by the observation that OSE tumor cells are 
closely associated with their surrounding stromal cells [140].  Interestingly, 
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conditioned media from normal stromal cells inhibits proliferation of SKOV3 and 
Caov3 OC cell lines in vitro  [136], while nude mice co-injected with SKOV3 or 
OCC1 OC cells and normal stromal cells display a slower onset of tumor 
formation and rate of tumor growth compared to mice injected with cancer cells 
alone [123].  Additionally, precursors of OSE tumors, such as hyper- and 
metaplastic changes of the OSE and associated inclusion cysts, are related to 
stromal hyperplasia [141].  In the present study, I found that stromal Bcl-2 
staining decreased with malignant progression and the intensity of stromal Bcl-2 
expression was inversely related to tumor grade, possibly suggesting that 
alterations in stromal components might promote tumor progression.  Taken 
together, these findings support a role of tumor-stromal interactions in the 
regulation of tumorigenesis as well as tumor progression in EOC. 
Lastly, OC is a highly immunogenic disease, which triggers the influx of a 
large number of lymphoid cells to the tumor site.  Lymphocytes play a major role 
in the host immune response since stimulated lymphocytes release cytokines, 
antibodies, and growth factors necessary for immune-mediated tumor cell lysis 
[142].  Consequently, the presence of T cells is generally associated with an 
improved clinical outcome in advanced ovarian carcinoma.  Adams et al. [143] 
showed that OC patients who have tumors with a high frequency of intraepithelial 
T cells, specifically CD8+ T cells, have a significantly better 5-year survival rate 
than patients whose tumors have  a low frequency of intraepithelial CD8+ T cells.  
Likewise, Clarke et al. found that the presence of intraepithelial CD3+ and CD8+ T 
cells was associated with improved survival in patients with serous ovarian 
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carcinomas, but not patients with endometrioid or clear cell carcinomas [127].  
These latter findings may be related to the presence of CD8+ T lymphocytes in 
underlying tumor stroma correlating with vascular invasion, thereby potentiating 
tumor growth in endometrioid carcinoma [125].  In the present study, I found an 
increased number of lymphocyte nests with malignant transformation in ovarian 
specimens and the size of lymphocytes nests also increased significantly with 
tumor progression; however, I did not have any information on patient survival to 
report any prognostic data.  Given that lymphocytes secrete TGF-β [144] which 
can promote mesenchymal cell growth [145], focal areas of lymphocytes, then, 
may support growth of higher grade ovarian tumors, especially as that pertains to 
ovarian epithelial cells that have undergone epithelial to mesenchymal transition 
characteristic of OC progression [146].  TGF-β is also thought to have angiogenic 
properties [147] which would additionally benefit tumor growth.  These findings of 
increased lymphoid aggregates present with OC progression are in agreement 
with other cancers including lymphoma [148], breast cancer [149], and 
melanoma [150]. However, whether these lymphocytes assist in the antitumor 
response or promote tumor growth remains unclear since the role that they play 
may very well be disease-specific.   
In this pilot study, then, it appears that alterations in Bcl-2 expression and 
the number of lymphocytes may be to be correlated with OC progression.  
Clearly, then, further studies with additional samples are warranted since, the 
combination of Bcl-2 expression and lymphocyte status may be important for 
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prognostic outcome or provide useful targets for therapeutic intervention in 
patients with EOC. 
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CHAPTER III 
LPA-MEDIATED EXTRACELLULAR BCL-2 PROMOTES ABERRANT 
ANGIOGENESIS 
 
Abstract 
Angiogenesis plays an important role in OC tumor growth and metastasis.  
The ovarian tumor microenvironment is comprised of tumor cells, surrounding 
stroma, and a host of circulating proteins.  Bcl-2, the prototypical anti-apoptotic 
protein, is overexpressed in ovarian tumors and contributes to neoplastic 
transformation and drug-resistant disease, resulting in poor clinical outcome.  
LPA is elevated in the plasma and ascites fluid of OC patients and has been 
proposed as a diagnostic tool for OC.  In addition, LPA elicits anti-apoptotic 
activity through upregulation of Bcl-2 in other systems.  Therefore, LPA 
regulation of Bcl-2 expression in OC was assessed using an in vitro cell culture 
model system.  IOSE 118 and OV2008, C13, and IGROV OC cells were treated 
± 10µM LPA.  LPA was found to increase Bcl-2 expression at the protein and 
message levels using western immunoblotting, ELISA, PCR analysis and 
luciferase reporter assays. Interestingly, LPA also promoted Bcl-2 secretion by 
OC cells, a novel action of Bcl-2.  In vitro HUVEC tube formation assays 
displayed promotion of aberrant tube formation by OC-derived and recombinant 
Bcl-2.  Bcl-2 appeared to modulate tube formation by inhibiting HUVEC 
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migration.  Given that both LPA and Bcl-2 are potential targets in OC 
intervention, elucidating their inter- and regulatory relationships, especially in 
angiogenesis, may be of clinical importance and warrants further investigation. 
 
Introduction 
OC, often referred to as the “silent killer”, remains the number one cause 
of death due to gynecologic malignancies among women in the United States.  
OC is often not diagnosed until stage III or IV, when the tumor has metastasized 
beyond the pelvis.  Patients diagnosed with advanced stages of OC have a 5-
year survival rate of less than 30%, whereas patients diagnosed in early stages 
have a 5-year survival rate of almost 95% [1] .  Though early stages of OC are 
generally asymptomatic, typical symptoms include urinary urgency, bloating, gas, 
nausea, and abdominal discomfort [151].  Further, OC patients often present with 
abdominal swelling due to accumulation of malignant ascites fluid in the 
peritoneal cavity most likely due to intraperitoneal spread of disease.  Ascites 
fluid can stimulate the proliferation of OC cells [87, 152], and, thus, has 
implications in the progression of OC.   
As with other vascularized tumors, the vessels in ovarian tumors differ 
from their normal counterparts.  Tumor blood vessels demonstrate various 
structural abnormalities (such as irregular diameters and blind ends) [112], in 
addition to dysregulated expression of growth factors, integrins, and receptors 
[106, 108, 113].   Furthermore, tumor blood vessels display marked leakiness 
which contributes to extravasation of blood cells and plasma proteins as well as 
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dissemination of tumor cells associated with metastases [153-155].  The pro-
angiogenic factor, VEGF, promotes peritoneal vessel permeability leading to 
ascites development in OC.  Likewise, VEGF is present at high levels in ovarian 
cyst fluid [156, 157] and ascites [158] of OC patients.  Other angiogenic factors 
that are elevated in the ascites fluid of OC patients include bFGF [159], 
endothelin-1 (ET-1) [160], interleukin-8 [161], angiogenin [159], and TGF-α and -
β [162].  Alternatively, ascites fluid contains high levels of anti-angiogenic factors, 
specifically, fibrinogen degradation products [163] and angiostatin [164], a 
product of plasminogen cleavage. Though the reason for the net anti-angiogenic 
activity of ovarian ascites fluid is poorly understood, angiostatin is implicated in 
the suppression of secondary tumor growth [165]. 
High levels of LPA are also detected in the ascites fluid and serum of OC 
patients [87-89].  LPA is also known as the “ovarian cancer activating factor”, due 
to its ability to stimulate the proliferation of cancer cells [88, 166].  In addition to 
its growth-inducing capabilities, LPA stimulates intracellular calcium release and 
tyrosine phosphorylation, including MAPK activation [88, 166].  Furthermore, LPA 
plays a role in sustained angiogenesis and evasion of apoptosis.  In OC cell 
lines, LPA help promotes tumor growth, angiogenesis, invasion and migration 
[93, 167] by transcriptional activation of VEGF.  In colon cancer cells, LPA 
upregulates the expression of the pro-apoptotic protein Bcl-2 while increasing 
phosphorylation of the anti-apoptotic Bad protein, providing protection from 
etoposide-induced apoptosis [168].  LPA also elicits anti-apoptotic activity by 
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promoting expression of Bcl-2 at both mRNA and protein levels in intestinal 
epithelial cells [95].   
This aim examined the effect of LPA on Bcl-2 expression in human 
immortalized ovarian surface epithelial cells and OC cell lines.  I found that LPA 
increased Bcl-2 expression in OC cell lines.  Upon analysis of the conditioned 
media, I observed that LPA also mediated Bcl-2 secretion from OC cell lines.  I 
then determined that extracellular Bcl-2 is related to aberrant endothelial tube 
formation. 
 
Materials and Methods 
 
Cell Lines and Reagents  
SV-40 large T antigen transfected OSE (IOSE 105, 114, 118, ILOW, and 
IMCC3) and ovarian carcinoma cell lines (C13, CaOV3, ES-2, IGROV, OV2008, 
OV-90, OVCAR5, PA-1, and SW626) were cultured in 199/MDCB 105 medium 
(Sigma Aldrich®, St. Louis, MO) supplemented with 5% Fetal Bovine Serum 
(FBS, SAFC Global®, St. Louis, MO) and 10µg/mL Gentamicin (GIBCO®, 
Carlsbad,CA).  Clonetics® Human Umbilical Vein Endothelial Cells (HUVECs) 
were cultured in EGM-2 medium (both from Lonza Walkersville, Inc., 
Walkersville, MD).  All cells were incubated at 37°C with 5% CO2. 
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Preparation of Conditioned Media and Cell Lysates  
To measure endogenous and LPA-induced levels of Bcl-2 in IOSE and 
OC cell lines, conditioned media and cell lysates were collected.  Cells were 
plated in 150mm petri dishes at a density of 4x106 and cultured for 24h.  For 
measurement of endogenous Bcl-2, fresh media was added 24h after plating and 
cell pellets and conditioned media were collected an additional 24h later.  For 
LPA treatments, 24h after plating, cells were cultured in serum-free media (0.1% 
FBS 199/105 medium) overnight.  Fresh serum-free media ± 10µM oleoyl-L-α-
LPA (Enzo Life Sciences, Plymouth Meeting, PA) was then added to the cells, 
and cell pellets and conditioned media, likewise, collected an additional 24h later.  
All cell pellets were lysed in CHAPS lysis buffer and conditioned media was 
concentrated using Amicon Ultra Centrifugal Filter Units with a molecular weight 
cutoff of 10 kDa (Millipore, Billerica, MA) according to the manufacturer’s 
instructions. 
 
Transient Transfections and Luciferase Assays 
Two million IOSE 118 and OV2008 OC cells were transiently transfected 
with 1μg Bcl-2 cDNA, 1.5μg full-length Bcl-2 promoter-luciferase reporter gene 
(both generously provided by Dr. Christina Pratt) or 1.5μg Green Fluorescent 
Protein (GFP; Lonza Walkersville, Inc., Walkersville, MD) using Amaxa® 
Nucleofector® kit V and program X-005 (Lonza Walkersville, Inc., Walkersville, 
MD).  For samples transfected with Bcl-2 cDNA or GFP, fresh media was added 
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to transfected cells 24h post-transfection.  Cells and conditioned media were 
collected 48h and 72h post-transfection.  For cells transfected with Bcl-2 
promoter, cells were treated ± 10µM LPA 24h post-transfection and lysed an 
additional 24h later.  Reporter gene activity was quantified with the Dual 
Luciferase® Assay (Promega Corporation, Madison, WI) per manufacturer’s 
instructions.  Firefly luciferase activities were normalized by Renilla luciferase 
activities and data expressed as the mean relative luciferase activities of triplicate 
samples ± standard error (SE).   
 
Enzyme-Linked Immunosorbant Assay 
Protein from lysed cells and concentrated conditioned media (CCM) were 
assayed for Bcl-2 by Bcl-2 enzyme-linked immunosorbant assay (ELISA) 
(Bender Medsystems, Burlingame, CA) according to the manufacturer’s protocol.  
Bcl-2 concentrations were determined by measuring sample absorbance at 
450nm using the ELx800 Universal Microplate Reader (Bio-Tek Instruments, Inc., 
Winooski, VT).  Bcl-2 concentrations were calculated using the absorbance of 
triplicate samples and expressed as the mean ± SE. 
 
Immunodepletion and Immunoprecipitation of CCM 
To determine the amount of total protein present in conditioned media 
samples, the Bio-Rad Dc Protein Assay (Bio-Rad, Hercules, CA) was used 
according to manufacturer’s protocol.  Immunodepletion (ID) or 
immunoprecipitation (IP) of Bcl-2 from CCM was achieved using a monoclonal 
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mouse anti-Bcl-2 antibody (SC-7) and Protein A/G PLUS Agarose Bead slurry 
(both from Santa Cruz Biotechnology, Santa Cruz, CA) according to 
manufacturer’s protocol.  ID media was used in subsequent endothelial tube 
assays and IP reactions analyzed via Western Blot. 
 
Western Blot Analysis 
For Western blot analyses, protein concentrations of cell lysates were 
determined using the Bio-Rad Dc Protein Assay (Bio-Rad, Hercules, CA) 
according to manufacturer’s instructions.  Protein extracts were solubilized in 
SDS gel loading buffer (60mM Tris base, 2% SDS, 10% glycerol, and 5% β-
mercaptoethanol).  ID CCM, IP reactions, or cell lysates were electrophoresed 
via 10% SDS-PAGE and transferred to Immobilon P PVDF membrane (Millipore, 
Billerica, MA) by wet transfer.  Membranes were blocked with 5% milk in tris-
buffered saline with tween for 1h at room temperature.  Membranes were then 
incubated in monoclonal mouse anti-Bcl-2 antibody overnight at 4°C followed by 
goat anti-mouse HRP-conjugated antibody (both from Santa Cruz Biotechnology, 
Santa Cruz, CA) for 1h at room temperature.  β-actin (Sigma Aldrich, St. Louis, 
MO) was used as a loading control.  Bands were detected with SuperSignal West 
Femto Substrate and/or Pierce ECL Western Blotting Substrate (both from 
Thermo Fisher Scientific, Inc., Rockford, IL) and densitometric analysis 
performed using ImageQuant 5.2 image analysis software (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ).  Bcl-2 intensity was normalized to β-actin and 
expressed as relative densitometric intensity. 
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Reverse Transcriptase Polymerase Chain Reaction 
To determine whether or not LPA-induced Bcl-2 upreguation was 
transcription-dependent, reverse-transcriptase polymerase chain reaction (RT-
PCR) was performed.  Briefly, total cellular RNA was collected using TRIzol 
reagent (Invitrogen, Carlsbad, CA).  Reverse transcription to single-strand cDNA 
was performed using 1µg of total mRNA, oligo(dT), and reverse transcriptase.  
Amplification of the cDNA was carried out using the GeneAmp® RNA PCR kit 
(Invitrogen, Carlsbad, CA).  The Bcl-2 primers used were Bcl-2 sense 5’-
GGTGCCACCTGTGGTCCACCTG-3’ and antisense 
5’CCTATCTGGGCCACAAGTGAAG-3’, with β-actin primers Actin sense 5’-
GGGAATTCAAAACTGGAACGGTGAAGG-3’ and Actin antisense 5’- 
GGAAGCTTATCAAAGTCCTCGGCCACA-3’ for an internal control. The 
amplified products were separated by electrophoresis on a 10% polyacrylamide 
gel, stained with 1x SYBR Green (Lonza Cologne GmbH, Germany) and 
photographed with Kodak KDS1D 2.0 image analysis software. 
 
Tube Assay 
In vitro tube formation assays were used to determine whether exogenous 
Bcl-2 contributes to angiogenesis.  HUVECs were cultured at a density of 5x104 
on a Matrigel (BD Biosciences, San Jose, CA) overlay in 24-well plates and 
supplemented with OC cell CCM ± Bcl-2 ID.  Alternatively, HUVECs were 
cultured at a density of 15x103 on a Matrigel overlay in 96-well plates ± 10µg/mL 
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recombinant human (rh) Bcl-2 (R&D Systems, Minneapolis, MN).  Tube formation 
was observed at 18-21h with an inverted microscope in three fields of triplicate 
wells or in 6 wells of 24- and 96-well plates, respectively.  Images were captured 
and analyzed using the Image Pro Plus Digital Imaging System (Media 
Cybernetics, Inc, Bethesda, MD).  The quantity of tube-like structure formation 
was determined and defined by four parameters:  number of polyhedral 
chambers, area of polyhedral chambers, total tube length, and number of free 
tubes.  Measurements were expressed as mean ± SE. 
 
Scratch Wound Assay 
In vitro scratch wound assays were used to determine whether exogenous 
Bcl-2 affected HUVEC migration.  HUVECs were plated in 60mm tissue culture 
dishes and grown to confluency.  Confluent monolayers of HUVECs were 
wounded using a 1mL micropipette tip and rinsed twice with PBS.  Cells were 
then cultured with EGM-2 media supplemented with OV-90 cell CCM ± Bcl-2 ID. 
Wound closure was monitored for up to 48h and photographed using a digital 
camera.  Scratch distances from eight microscopic fields in each condition were 
measured at specified time points using Image Pro Plus Digital Imaging System 
(Media Cybernetics, Inc, Bethesda, MD) and graphed as the mean ± SE.    
 
Measurement of Cell Proliferation 
HUVEC viability was detected using the CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay (Promega Corporation, Madison, WI), a 
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colorimetric assay based on soluble formazan production by dehydrogenase 
enzymes found in metabolically active cells.  Cells were plated at 5x103 cells per 
well in triplicate.  Absorbance was measured at 490nm using the ELx800 
Universal Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT).  Results 
were expressed as the percentage of control absorbance ± SE. 
 
Statistical Analysis 
Where applicable, Student’s t test was performed for determination of 
statistical significance between control and treated samples and P values are 
reported in the respective figures. 
 
Results 
 
OC Cell Lines Express More Bcl-2 than IOSE Cell Lines 
Endogenous levels of Bcl-2 were examined in a panel of 5 normal IOSE 
cell lines (105, 114, 118, ILOW, and IMCC3) and 9 OC cell lines (C13, CaOV3, 
ES-2, IGROV, OV2008, OV-90, OVCAR5, PA-1, and SW626).  OC cell lines 
displayed overall higher cellular levels of Bcl-2 (Figure 10a).  The average 
cellular Bcl-2 expression in the normal IOSE cells was only 62% of the cellular 
Bcl-2 seen in the OC cell lines (Figure 10a, inset).  Interestingly, while IOSE cell 
lines from patients with a known familial history of ovarian or breast cancer 
(FHIOSE:  105, 114, and 118) had secreted Bcl-2 levels more than 2-fold higher 
than IOSE cell lines from patients without a known familial history of ovarian or  
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Figure 10.  Intracellular and extracellular Bcl-2 levels are elevated in OC cell 
lines.  A.  Endogenous cellular Bcl-2 protein was measured in IOSE (105, 114, 
118, ILOW, and IMCC3) and OC (C13, CaOV3, ES-2, IGROV, OV-90, OVCAR5, 
PA-1, and SW626) cells using Bcl-2 ELISA.  Results are expressed as the mean 
of triplicate samples ± SE.  Inset:  Bcl-2 values for IOSE (normal) and OC 
(cancer) cells were combined and results expressed as the mean ± SE.  B.  Bcl-2 
was immunoprecipitated from CM of IOSE and OC cultured for 24h.  IP reaction 
was analyzed via SDS-PAGE and probed for Bcl-2.  Results represent relative 
densitometric intensity normalized to cell count upon collection of CM.  Inset:  
Densitometric intensity from NFHIOSE (ILOW and IMCC3; Normal) and OC 
(cancer) cells were combined and results expressed as mean relative 
densitometric intensity. 
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breast cancer (NFHIOSE; ILOW and IMCC3) and most of the OC cell lines 
(Figure 10b), the average secreted Bcl-2 of the NFHIOSE cell lines was almost 
60% lower than that of the OC cell lines (Figure 10b, inset).  Therefore, cellular 
and secreted Bcl-2 levels were generally higher in OC cells. 
 
Overexpression of Bcl-2 Promotes Its Secretion 
To determine if secretion of Bcl-2 is exacerbated by its overexpression, 
the OC cell line OV2008 was transiently transfected with full length Bcl-2 cDNA.  
Transfection was confirmed by measuring cellular Bcl-2 levels via Bcl-2 ELISA 
(Figure 11a).  Bcl-2 cDNA elicited increases of at least 5- and 17-fold in cellular 
(Figure 11a) and secreted (Figure 11b) Bcl-2, respectively, compared to cells 
transfected with GFP.  Additionally, cellular increases in Bcl-2 preceded the rise 
of Bcl-2 secretion, suggesting that cellular Bcl-2 levels may reach a threshold, 
resulting in further Bcl-2 secretion. 
 
LPA Increases the Expression of Bcl-2 
Since LPA has previously been shown to upregulate Bcl-2 in epithelial 
cells [95], I assessed whether LPA increases Bcl-2 expression and/or secretion 
in IOSE and OC cell lines.  I found that LPA increased cellular Bcl-2 expression 
(Figure 12A) and secreted Bcl-2 (Figure 12B) by up to two-fold and 10%, 
respectively.  Bcl-2 levels were unchanged with LPA treatment in IOSE 118 cells 
(Figure 12A and 12B).  Likewise, LPA amplified Bcl-2 mRNA expression by up to 
9-fold in OC cell lines, while IOSE 118 mRNA levels were unchanged by LPA 
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Figure 11.  Bcl-2 overexpression increases cellular and extracellular Bcl-2 
levels.  OV2008 cells were transiently transfected with Bcl-2 cDNA.  Fresh media 
was added 24h post-transfection followed by collection of cell pellets and 
conditioned media an additional 24 and 48h later.  Cellular (A) and extracellular 
(B) Bcl-2 protein was measured in duplicate samples via Bcl-2 ELISA and 
expressed as mean ± SE. 
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Figure 12.  LPA enhances cellular and secreted Bcl-2 Levels.  IOSE 118, 
OV2008, C13, and IGROV cells were serum-starved overnight and treated ± 
10µM LPA for 24h.  A.  Cell lysates were subjected to SDS-PAGE and Western 
immunoblot for Bcl-2.  Bcl-2 levels were normalized to β-actin.  Data is graphed 
as fold change in relative densitometric intensity.  B. Bcl-2 protein in CCM was 
analyzed by Bcl-2 ELISA and results expressed as mean of duplicate samples. 
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(Figure 13A).  Further, LPA did not affect IOSE 118 Bcl-2 promoter activity 
(Figure 13B).  It did, however, increase Bcl-2 promoter activity by more than 60% 
in the OV2008 OC cells (Figure 13B).  Together, these data suggest that LPA-
induced Bcl-2 upregulation is transcriptionally dependent.   
 
Extracellular Bcl-2 Affects Angiogenesis 
Bcl-2 expression levels in tumor vasculature-associated endothelial cells 
have been correlated with tumor angiogenesis and growth [169, 170].  However, 
the effect(s) of extracellular Bcl-2 on angiogenesis has not been investigated.  
Removal of Bcl-2 from OV2008 CCM via ID was verified by western blot (Figure 
14A).  HUVECs cultured with Bcl-2 ID CCM had almost 40% more polyhedral 
chambers and produced a 25% longer tube-like network than HUVECs grown in 
the presence of Bcl-2 (Figure 14B and 15).  Additionally, HUVECs grown without 
Bcl-2 showed 67% smaller chambers and 44% fewer free-ended tube-like 
structures (Figure 15) than HUVECs grown with Bcl-2.  To verify the relationship 
between Bcl-2 and aberrant endothelial tube formation, tube assays were 
performed with rhBcl-2.  In agreement, HUVECs cultured without rhBcl-2 had 
60% more polyhedral chambers than their Bcl-2 treated counterparts (Figure 16).  
HUVECs cultured without rhBcl-2 also formed 20% more tube-like structures 
overall and had 25% smaller chambers than the HUVECs cultured with rhBcl-2, 
though these measurements did not quite reach statistical significance (Figure 
16).  However, in contrast to the tube assays performed with OC cell CCM, 
HUVECs grown with rhBcl-2 had 15% fewer free ended tube-like structures than  
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Figure 13. LPA increases Bcl-2 mRNA levels and promoter activity.  A.  
IOSE 118, IGROV, and OV2008 cells were serum-starved overnight and treated 
± 10µM LPA for 24h and examined by RT-PCR for Bcl-2 and β-actin.  PAGE 
following RT-PCR revealed a 459 bp Bcl-2 product and a 98 bp Actin product.  
Bcl-2 band intensities were normalized to respective actin intensities and fold 
change between control and treated samples was calculated and noted below 
the bands.  B.  IOSE 118 and OV2008 cells were transiently cotransfected with 
full-length Bcl-2 promoter luciferase reporter plasmid and Renilla hRluc luciferase 
reporter plasmid.  Twenty-four hours post-transfection, cells were treated ± 10µM 
LPA for 24h.  Firefly luciferase activity was normalized to Renilla luciferase 
activity and expressed as mean relative luciferase activity ± SE for triplicate 
samples.
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Figure 14.  Bcl-2 promotes aberrant endothelial tube formation.  A.  Bcl-2 
was immunoprecipitated from OV2008 CCM.  IP reaction (control) and 
supernatant (Bcl-2 ID) were analyzed via SDS-PAGE by probing with Bcl-2.  
Supernatant was saved for subsequent endothelial tube assays. B.  
Representative photograph (40X magnification) of Matrigel tube formation assay 
in which HUVECs were cultured with OV2008 CCM ± Bcl-2 ID for 18-21h.
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Figure 15.  Differences in angiogenesis parameters ± OC cell-derived Bcl-2.  
Following endothelial tube formation assays, angiogenesis parameters were 
quantified in three fields of triplicate wells for each condition and graphed as 
mean measurements ± SE.  
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Figure 16.  Differences in angiogenesis parameters ± rhBcl-2.  Following 
endothelial tube formation assays, angiogenesis parameters were quantified in 
three fields of triplicate wells for each condition and graphed as mean 
measurements ± SE.  
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controls, though this difference did not reach statistical significance (Figure 16).  
Collectively, these findings suggest that extracellular Bcl-2 may play a role in 
angiogenesis, specifically promoting aberrant tube formation. 
 
Extracellular Bcl-2 Reduces Endothelial Cell Migration 
To begin to understand the mechanisms by which exogenous Bcl-2 can 
promote aberrant tube formation, in vitro wound assays and MTS assays were 
performed to assess endothelial cell migration and cell proliferation, respectively.  
HUVECs cultured without Bcl-2 migrated approximately 15% faster than 
HUVECs cultured in the presence of Bcl-2 at both 24 and 30h (Figure 17A).  The 
statistical difference in migration at 24h is noteworthy because this coincides with 
the time that tube formation was quantified.  In contrast, addition of rhBcl-2 did 
not significantly affect HUVEC viability (Figure 17B).  These initial studies, 
therefore, suggest that exogenous Bcl-2 may promote aberrant tube formation by 
inhibiting endothelial cell migration. 
 
Discussion 
Bcl-2 was originally identified as the deregulated oncoprotein associated 
with the t(14:18) chromosome translocations commonly found in B-cell 
lymphomas [37, 171].  Bcl-2 is the founding member of the Bcl-2 family of 
proteins involved in regulation of apoptosis.  The family consists of anti-apoptotic 
(e.g. Bcl-2, Mcl-1, Bcl-XL) and pro-apoptotic members (e.g. Bax, Bad, Bim).  The 
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Figure 17.  Bcl-2 reduces HUVEC migration but not cell viability.  A.  
Confluent monolayers of HUVECs were wounded with a micropipette tip and 
cultured with OV-90 CCM ± Bcl-2 ID.  Scratch distances from eight microscopic 
fields were measured at 0, 6, 24, and 30h and graphed as mean distance ± SE.  
B.  HUVECs were cultured ± rhBcl-2 and cell viability was measured by MTS at 0 
and 24h following treatment.  Cell viability from triplicate samples is expressed as 
percentage of control ± SE.  
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pro-apoptotic Bcl-2 family members homodimerize, causing permeabilization of 
the outer mitochondrial membrane and release of cytochrome C which leads to 
caspase activation and, ultimately, apoptosis.  The anti-apoptotic family members 
function to secure the outer mitochondrial membrane’s integrity by forming 
heterodimers with the pro-apoptotic family members thereby directly inhibiting 
their apoptotic activity [42].  Bcl-2 is the prototypic anti-apoptotic Bcl-2 family 
member and is elevated in a number of solid tumors, including ovarian 
carcinomas [172].   
Currently, I confirmed that Bcl-2 levels were significantly higher in OC cell 
lines compared to normal IOSE cell lines.  I also found that both OC and IOSE 
cells secrete Bcl-2.  Of interest, IOSE from patients with a familial history of 
ovarian or breast cancer secreted higher levels of Bcl-2.  Studies correlating Bcl-
2 expression with familial history of cancer are few and contradictory.  Bauer, et 
al. found that Bcl-2 did not significantly correlate to a positive familial history in 
patients with prostate cancer [173].  Similarly, Bcl-2 expression did not differ 
between sporadic and hereditary medullary thyroid carcinomas [174].  On the 
other hand, Piek et al. [175], observed higher Bcl-2 levels in surface and 
inclusion cyst epithelium of prophylactically removed ovaries from women with a 
hereditary predisposition for female adnexal cancer.  While Bcl-2 is expressed at 
lower levels in patients with BRCA1-associated breast cancers [176, 177], we 
recently found that women with a familial history of breast or OC have elevated 
urinary Bcl-2 ([135], Chapter 4).  Both Bcl-2 and Bcl-x expression were increased 
in patients with hereditary leiomyomatosis and renal cell carcinoma, however, 
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Bak expression was decreased in these patients [178].  Additionally, loss of Bax 
expression is associated with hereditary non-polyposis colorectal cancer [179, 
180].  Different alterations in apoptotic machinery, then, may specifically 
contribute to some sporadic and hereditary cancers. 
Given that Bcl-2 is generally described as an intracellular protein localized 
to the outer mitochondrial membrane, ER, or perinuclear membrane [43, 44], in 
vitro secretion of Bcl-2 reported herein is novel.  Though serum Bcl-2 levels have 
been evaluated in a variety of illnesses [181-186] and the cerebral spinal fluid of 
patients with traumatic brain injury [187, 188], there are limited studies on the 
effects of extracellular Bcl-2 both in vivo and in vitro.  In mice, exogenously 
administered rhBcl-2 or rhBcl-2A1 were able to protect hind limb skeletal muscle 
or cardiac muscle from ischemia-reperfusion injury [189], leading Iwata et al. to 
suggest that Bcl-2, Bcl-2A1, and BH4-domain peptides are among an enlarging 
group of danger-associated molecular patterns (DAMPs).  DAMPs or ‘alarmins’ 
are intracellular constituents that act extracellularly to engage receptors on 
immune or adjacent cells and facilitate activation of the innate immune system.  
Iwata’s group deduced that the cytoprotective effect of Bcl-2, Bcl-2A1, and their 
BH4 peptides was mediated via toll-like receptor 2 (TLR2) signaling through a 
MyD88-dependent pathway.  Perhaps, then, secreted Bcl-2 in ovarian systems 
may likewise enhance immune response and result in increased presence of 
lymphocytes as noted with OC progression in chapter 2. 
This study is not the first to observe extra-apoptotic Bcl-2 functions.  
However, this is the first report of aberrant tube formation associated with 
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extracellular Bcl-2.  Interestingly, Bcl-2 has been shown to influence axonal 
elongation and outgrowth [190-192].  Ureteric bud cells lacking intracellular Bcl-2 
demonstrated:  1) faster cell migration; 2) increased invasion; 3) decreased 
thrombospondin-1 and osteopontin expression; 4) increased expression of α1- 
and α2-integrin subunits; and 5) increased fibronectin expression [193] compared 
to those expressing Bcl-2.  Though these experiments dealt with the effects of 
intracellular Bcl-2, my findings are similar such that removal of extracellular Bcl-2 
increased endothelial cell migration.  Overexpression of Bcl-2 in mammary 
epithelial cells promoted multilayering of cells and formation of three-dimensional 
structures at confluence.  Bcl-2 also facilitated the formation of branching 
structures in collagen gels, suggesting that Bcl-2 may assist in differentiation in 
the mammary gland [194].  Additionally, in mammary epithelial cells, Bcl-2 
overexpression did not promote tumorigenesis.  In contrast, endothelial cells 
cultured without Bcl-2 had a higher propensity for tube-like structure formation 
compared to the aforementioned studies [193, 194] which observed increased 
tube-like structures in ureteric bud and mammary epithelial cells with Bcl-2.  The 
differences between the morphogenetic properties of Bcl-2 could be due to the 
distinct cell types or signaling pathways activated by extracellular Bcl-2.  For 
instance, Segura, et al., found that overexpression of Bcl-2 in HUVEC resulted in 
impaired vessel-like structure formation in vitro and that pharmacological 
inhibition of apoptosis, using caspase inhibitors, blocked VEGF-dependent 
vascular formation in vivo [107].  Likewise, cell viability did not influence Bcl-2-
mediated decreases in vessel-like tube formation in the present study.  Since 
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extracellular Bcl-2 maintains its anti-apoptotic activity [189], the current findings 
support the theory that early stages of angiogenesis require apoptosis for proper 
vascular network formation.  This is further supported by studies showing that 
apoptosis is needed for proper remodeling [195] and lumen formation [196] 
involved in angiogenesis. 
Lastly, secretion of Bcl-2 was enhanced by LPA in this study.  It is well 
known that LPA is elevated in serum and ascites fluid of OC patients [87, 88] 
and, thus, has been considered as a biomarker for OC [89].  LPA stimulates 
VEGF expression in OC cell lines [93], indirectly stimulating ovarian tumor 
growth, in part, by increasing angiogenesis via VEGF.  Our group has previously 
shown that LPA may also promote OC cell survival through VEGF-mediated 
upregulation in telomerase activity [197].  Further, in addition to its pro-
angiogenic activity, VEGF also aids in endothelial cell survival by upregulating 
anti-apoptotic proteins Bcl-2 and Bcl-2A1 [198].  Though the current study did not 
determine whether LPA-mediated Bcl-2 secretion was VEGF-dependent, the 
findings herein suggest that tumor-secreted Bcl-2 may be yet another component 
of a paracrine loop between ovarian tumor and endothelial cells involved in 
modulation of angiogenesis. 
In conclusion, Bcl-2 may play a dual role in tumorigenesis, through its anti-
apoptotic function, which promotes tumor cell growth and confers 
chemoresistance, and by contributing to abnormal formation of tumor 
vasculature.  In the latter context, it is tempting to speculate that extracellular Bcl-
2 could promote abnormal vessel structure in ovarian tumors by altering 
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endothelial cell migration and remodeling, ultimately contributing to drug 
resistance by limiting therapeutic access to tumor cells.  Finally, further studies 
on the mechanism(s) of extracellular Bcl-2 function are warranted given its 
potential as a target for therapeutic intervention. 
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CHAPTER IV: 
URINARY LEVELS OF BCL-2 ARE ELEVATED IN OVARIAN CANCER 
PATIENTS 
 
Abstract 
The poor prognosis associated with OC is due to the lack of overt early 
symptoms and the absence of reliable diagnostic screening methods.  Since 
many tumors overexpress anti-apoptotic proteins, the purpose of this study was 
to determine whether elevated levels of the anti-apoptotic protein Bcl-2 were 
present in urine from patients with OC.  Bcl-2 was assayed by ELISA in urine 
samples from two cohorts consisting of a total of 77 healthy women, 161 women 
with benign gynecologic disease and 150 women with OC, 13 with early and 137 
with late stage disease, respectively.  Wherever possible, parallel serum samples 
were measured for CA125 levels by ELISA.  Urinary levels of Bcl-2 from healthy 
individuals or women with benign disease averaged 0.59 ng/ml ± 0.61 and 1.12 
ng/ml ± 0.79, respectively.  In contrast, urinary levels of Bcl-2 averaged 2.60 
ng/ml ± 2.23 and 3.58 ng/ml ± 1.55 from women with early (N=13) and late 
(N=137) stage OC.  Further, urinary levels of Bcl-2 were elevated in OC patients 
regardless of tumor grade, stage, size, histologic subtype, creatinine levels or 
patient age, but appeared to complement CA125 measurements.  Levels of Bcl-2 
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are elevated in the urine of patients with OC and may be of diagnostic and/or 
prognostic clinical importance.  Further studies of urinary Bcl-2 as a biomarker for 
OC alone or in combination with other markers are warranted. 
 
Introduction 
OC is the fifth leading cause of cancer death among women after lung, 
breast and colorectal cancer and is associated with a 1.7% lifetime risk [199].  
The lack of early, overt symptoms and the absence of a reliable screening test 
result in over 70% of women being diagnosed after the disease has spread 
beyond the ovary so that the prognosis is poor (5-year survival is no better than 
37%). For women at high risk for developing OC, annual pelvic examination, 
transvaginal ultrasound, and/or measuring blood levels for CA125 are the 
generally recommended screening methods available for detection of OC. 
However, use of these techniques for screening purposes is limited [200]. 
To safely and economically detect cancer with no or minimal invasiveness, 
previous studies have examined biological fluids for detectable cancer 
biomarkers. These include examining serum levels of soluble interleukin-2 as a 
marker for hematological malignancies [201], prostate-specific antigen and 
insulin-like growth factor binding protein-3 in nipple aspirate fluid from breast 
cancer patients [202] and urine levels of angiostatin and plasminogen or survivin 
for the detection of bladder cancer and sarcoma, respectively [203, 204]. In the 
ovary, in addition to elevated serum CA125, LPA is also found in high levels in 
plasma and ascites of OC patients and is considered a potential diagnostic 
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marker for OC [205]. Likewise, Hazelton et al [157] showed high levels of VEGF 
in cysts from OCs compared to cystic fluid from benign, borderline or functional 
cysts. However, the invasive nature for cystic fluid collection prohibits widespread 
use for general screening/diagnostic purposes. Strategies using multiple serum 
markers may increase sensitivity for OC detection, but have yet to provide useful 
and cost-effective screening [206]. Proteomic analysis can distinguish OC sera 
from those of healthy women. Individual proteomic biomarkers still require 
validation and the use of protein profiles has been hampered by the difficulties in 
defining optimal algorithms and inter-assay variability [207]. Recently, elevated 
serum and urinary levels of mesothelin have also been associated with OC [208]. 
Deregulation of apoptosis due to overexpression of anti-apoptotic proteins 
contributes to the malignant phenotype by supporting cancer cell growth and 
therapeutic resistance. Since the anti-apoptotic protein, Bcl-2, is overexpressed 
in OCs [59] and secreted by OC cells in culture (Chapter 3), I sought to assess 
whether elevated urinary levels of Bcl-2 are associated with OC. 
 
Methods and Materials: 
 
Patient cohort 
With prior institutional approval, urine and blood samples were collected 
from an initial cohort of healthy controls (N=19), women with benign gynecologic 
disorders (N=38) and patients with early (eOC, N=4) and late (lOC, N=31) stage 
OC at the H. Lee Moffitt Cancer Center at the University of South Florida (USF). 
All except 8 specimens were collected prior to initial surgical cytoreduction while 
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the latter 8 specimens presented with recurrent disease at the time of enrollment 
in this study. The cancer category consisted of women diagnosed with OC and 
primary peritoneal cancer, which is often related to OC. The samples collected 
from women with benign gynecologic disease consisted of broad range of non-
malignant gynecologic disorders. The second blinded urine sample cohort 
collected with IRB approval through the tissue bank at the M.D. Anderson Cancer 
Center (MDA) consisted likewise of healthy controls (N=58), women with benign 
gynecologic disease (N=123) and women with eOC (N=9) and lOC (N=106).  
Though these cohorts comprise a small pilot study (Table 4), they are 
representative of a typical clinical practice with regards to histology, grade and 
stage distribution.  
Paraffin blocks were identified, where possible, and the slides reviewed to 
confirm the histologic diagnosis according to FIGO scores. Annonymized 
information regarding patient age, tumor type, stage, grade, size and CA125 
values was also obtained as per availability. 
 
Sample Preparation 
Urine and blood samples were collected from patients, annonymized, and 
decoded to protect patient identity, and released from the tissue banks for this 
research project. All samples were kept in ice following collection. USF urine 
samples were treated with a standard protease inhibitor cocktail (80 µg/ml 4-(2 
aminoethyl)-benzene sulfonyl fluoride, 200 µg/ml EDTA, 0.2 µg/ml leupeptin, 0.2 
79 
 
TABLE 4.  Histologic diagnoses and clinical characteristics of the study 
population. 
 Years (mean ± SD; range) Sample Number 
USF Cohort 
Normal 
Benign 
Cysts 
Serous Cystadenoma 
Leiomyoma 
Adenofibroma 
Mucinous Cystadenoma 
Teratoma 
Polycystic Disease 
Ovarian Cancer 
Histotype: 
Endometrioid 
Mucinous 
Peritoneal 
Serous 
Stage 
I 
II 
III 
IV 
Grade 
1 
2 
3 
 
54.49 ± 12.7; 29-81 
55.90 ± 13.9; 28-84 
 
 
 
 
 
 
 
66.21 ± 13.8; 26-92 
 
n=19 
n=38 
10 
10 
9 
4 
2 
2 
1 
n=35 
 
1 
7 
2 
25 
 
3 
1 
23 
8 
 
8 
10 
17 
 
MDA Cohort 
Normal 
Benign 
Cysts 
Serous Cystadenoma 
LMP 
High Risk 
Leiomyoma 
Teratoma 
Endometriosis 
Serous Cystadenofibroma 
Fibroma 
Endometrial Hyperplasia 
Mucinous Cystadenoma 
Adenomyosis 
Brenner Tumor 
 
63.31 ±6.56; 51-77 
49.48 ± 14.19; 19-81 
 
n=58 
n=123 
31 
19 
14 
13 
12 
11 
8 
4 
3 
3 
2 
2 
1 
 
Ovarian Cancer 
Histotype 
Serous 
Endometrioid 
Mucinous 
Granulosa 
Stage 
I 
II 
III 
IV 
60.51 ± 12.27; 33-88 n=115 
 
99 
12 
3 
1 
 
6 
3 
90 
16 
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µg/ml pepstatin, Sigma Scientific, St. Louis, MI) and centrifuged at 3000 x g. 
Urinary supernates and plasma samples were then aliquoted and stored at -
20oC. Urine samples from MDA were likewise centrifuged, but without addition of 
protease inhibitors and the supernatants aliquoted and frozen at -80oC. 
 
Bcl-2 ELISA 
To measure Bcl-2 levels in patients’ urine, samples were assayed using a 
quantitative sandwich Bcl-2 ELISA (Bender MedSystems, Burlingame, CA) 
according to the manufacturer’s instructions. In accordance with previous studies 
[208], urinary Bcl-2 threshold levels were set to include 95% of Bcl-2 values of 
urine samples from healthy women. When not derived from clinical data, CA125 
levels in subjects’ plasma were assayed by ELISA (Bio-Quant, San Diego, CA) 
according to the manufacturer’s instructions. The enzymatic reactions were 
detected at 450 nm using a Dynex MRX plate reader (Dynex Technologies, 
Chantilly, VA) and Bcl-2 results expressed as the mean absorbance of triplicate 
samples ± SE, while CA125 results were expressed as the mean of duplicate 
samples. 
 
Statistical Analysis 
Samples for Bcl-2 ELISA were run in triplicate and the data subjected to 
descriptive, one way ANOVA, Tukey and ROC-AUC analyses. 
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Results 
 
Urinary Levels of Bcl-2 are Elevated in Patients with OC from the USF Cohort 
Since a standard cutoff threshold value for urinary Bcl-2 has not been 
established, I used the 95th percentile of Bcl-2 values for healthy controls as the 
threshold as previously employed to determine threshold values for urinary 
mesothelin [208]. The amount of urinary Bcl-2 was generally negligible (average 
0.30 ng/ml) in healthy control samples (Fig. 18A, Table 5) with no samples above 
the determined threshold of 1.7856 ng/ml. Similarly, urinary Bcl-2 levels from 
women with benign gynecologic disease were low averaging 0.74 ng/ml (Fig. 
18B, Table 5). In contrast, urinary Bcl-2 associated with ovarian and primary 
peritoneal cancer was generally >10x that found in normal control. Interestingly, 
only two OC samples exhibited Bcl-2 levels below the threshold level (1.12 ng/ml 
and 1.78 ng/ml), but it is noteworthy that these samples were derived from 
patients with mucinous OC. Further of note, a single benign sample and a single 
OC sample patient demonstrated extremely elevated urinary Bcl-2 levels in the 
absence of other notable clinical symptoms. Since these two extreme values 
were greater than the mean + 2.58 SD, they were omitted from the summarial 
box plots (Fig. 19A). Because ANOVA tests revealed significant differences 
among the four ovarian samples (F value = 64.48, p<0.001), pair-wise 
comparisons were used in further Tukey analyses (Table 6). These latter 
analyses indicated significant differences in urinary Bcl-2 between healthy 
controls and benign samples, between healthy controls and cancer samples as
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Figure 18.  Urinary Bcl-2 levels are elevated in OC patients. As representative, urinary samples are shown from the 
USF cohort examined by ELISA for Bcl-2 levels in normal healthy controls and OC patients (A) and in benign samples (B). 
Samples were examined in triplicate and the data expressed as the average ng/ml of Bcl-2 ± SE.  Cancer samples were 
subdivided into histologic subtype: endometrial (white bars), mucinous (striped bars), primary peritoneal (checkered bars) 
and serous carcinomas (grey bars) and the latter further subdivided by tumor grade. Urinary sample #41 from an OC 
patient was included in (B) to serve as a positive control
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TABLE 5.  Elevated urinary Bcl-2 in cohorts as descriptive statistical 
information. 
Type 
 
# Mean SD Median Min Max 
 
USF 
Normal 
Benign 
eOC 
lOC 
 
 
 
19 
38 
4 
31 
 
 
0.30 
0.74 
2.38 
2.54 
 
 
0.39 
0.66 
0.75 
1.83 
 
 
0.15 
0.68 
2.10 
3.17 
 
 
0 
0.10 
1.86 
1.12 
 
 
1.26 
3.99 
3.48 
9.80 
MDA 
Normal 
Benign 
eOC 
lOC 
 
 
58 
123 
9 
106 
 
0.69 
1.23 
2.70 
2.30 
 
0.64 
0.79 
2.68 
1.34 
 
0.57 
1.20 
1.94 
1.94 
 
0 
0 
1.05 
0 
 
2.55 
3.82 
9.65 
8.78 
USF + MDA 
Normal 
Benign 
eOC 
lOC 
 
77 
161 
13 
137 
 
0.59 
1.12 
2.60 
3.58 
 
0.61 
0.79 
2.23 
1.55 
 
0.39 
1.05 
1.96 
2.13 
 
0 
0 
1.05 
0 
 
2.55 
4.00 
9.65 
9.80 
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Figure 19.  Urinary Bcl-2 levels are elevated in OC patients. Urinary samples 
from the USF (A), MDA (B) and combined USF + MDA (C) cohorts were 
examined by ELISA for Bcl-2 levels in normal healthy controls, women with 
benign disease and early and late stage OC patients. Samples were examined in 
triplicate, the data expressed as the average ng/ml of Bcl-2 ± SD and graphed as 
box plots.
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TABLE 6.  Elevation of urinary Bcl-2 from healthy women and from patients with benign lesions, early (eOC) and 
late (lOC) stage ovarian cancer. 
  
ROC-AUC 
 
95% 
 
Tukey Mean Difference 
 
95% CI 
 
USF 
Normal vs. Benign 
Normal vs. All Cancer 
Normal vs. eOC 
Normal vs. lOC 
Benign vs. All Cancer 
Benign vs. eOC 
Benign vs. lOC 
eOC vs. lOC 
 
 
83% 
100% 
100% 
100% 
ND 
ND 
ND 
ND 
 
15.8% 
100% 
100% 
100% 
ND 
ND 
ND 
ND 
 
0.3586 
2.9193 
2.0829 
3.0308 
2.5607 
1.7243 
2.6722 
0.9478 
 
0.4568 
2.2938 
0.4936 
2.1838 
2.0419 
0.2037 
1.9624 
-0.58898 
 
1.17* 
3.55* 
3.67* 
3.88* 
3.08* 
3.24* 
3.38* 
2.48 
MDA 
Normal vs. Benign 
Normal vs. All Cancer 
Normal vs. eOC 
Normal vs. lOC 
Benign vs. All Cancer 
Benign vs. eOC 
Benign vs. lOC 
eOC vs. Loc 
 
 
71% 
90% 
90% 
90% 
ND 
ND 
ND 
ND 
 
17.9% 
50.4% 
44.4% 
50.9% 
ND 
ND 
ND 
ND 
 
0.5425 
1.5219 
1.1355 
1.5513 
0.9794 
0.593 
1.0088 
0.4158 
 
0.1608 
1.1686 
0.2316 
1.1592 
0.6944 
-0.2815 
0.6904 
-0.4632 
 
0.92* 
1.87* 
2.04* 
1.94* 
1.26* 
1.47 
1.33* 
1.29 
 
USF + MDA 
Normal vs. Benign 
Normal vs. All Cancer 
Normal vs. eOC 
Normal vs. lOC 
Benign vs. All Cancer 
Benign vs. eOC 
Benign vs. lOC 
eOC vs. lOC 
 
71% 
93% 
92% 
93% 
ND 
ND 
ND 
ND 
 
17.39% 
76.67% 
66.23% 
77.37% 
ND 
ND 
ND 
ND 
 
0.5061 
1.8512 
1.4172 
1.8897 
1.3451 
0.9111 
1.3837 
0.4725 
 
0.0834 
1.5286 
0.4714 
1.4545 
1.0831 
-0.001 
1.0275 
-0.4455 
 
0.93* 
2.17* 
2.36* 
2.32* 
1.61* 
1.82 
1.74* 
1.39 
ND, not determined;  *p<0.01 
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well as between benign samples and cancer samples. ROC-AUC analyses 
indicated that every cancer sample (both eOC and lOC) were above the 
threshold (Table 6). Lastly, I did not detect any significant change in urinary Bcl-2 
levels when representative samples were tested following repeated freeze thaws 
(up to 3 times), following storage at -20o or -80o C (> 3 months for each 
temperature) or at 4oC for one week (data not shown). 
 
Urinary Levels of Bcl-2 are Elevated in OC Patients from the MDA Cohort 
For validation purposes, urinary Bcl-2 levels were measured in a second 
sample cohort obtained from MDA. In agreement with the USF cohort, urinary 
Bcl-2 was low in healthy control or benign samples (average 0.69 ng/ml and 1.23 
ng/ml, respectively) (Table 5). Urinary Bcl-2 associated with OC was elevated 
and averaged 2.70 ng/ml and 2.30 ng/ml from eOC and lOC, respectively. In 
contrast to the USF cohort, however, some eOC and lOC samples fell below the 
determined threshold and may reflect differences in the cohorts especially as that 
may pertain to sample preparation and storage. Also as above, since a single 
eOC and lOC sample demonstrated extreme values were greater than the mean 
+ 2.58 SD, they were omitted from the summarial box plots (Fig. 19B). Because 
ANOVA tests revealed significant differences among the four ovarian samples (F 
value = 40.84, p<0.001), pair-wise comparisons were used in further Tukey 
analyses (Table 6). These latter analyses indicated significant differences in 
urinary Bcl-2 between healthy controls and benign samples and between healthy 
controls and cancer samples. While benign samples tended to be lower than 
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eOC, they were not statistically significant and there were no differences 
between eOC and lOC. ROC-AUC analyses also indicated that over 50% of 
cancer samples were above the threshold (Table 6). 
When the data from both USF and MDA cohorts was combined (Fig. 19C, 
Tables 5 & 6), urinary Bcl-2 levels in OC remained elevated. That is, urinary Bcl-
2 levels among healthy and benign samples (averages 0.59 ng/ml and 1.12 
ng/ml, respectively) were statistically lower than those from eOC and lOC 
(averages 2.60 ng/ml and 3.58 ng/ml, respectively). 
 
Surgical Debulking Reduces Urinary Levels of Bcl-2 
Levels of urinary Bcl-2 were compared in 7 OC patients immediately prior 
to (Fig. 20, black bars) and within 2 weeks following initial cytoreductive surgery 
(Fig. 20, white bars). Though this subset represents a small sample size, Bcl-2 
levels decreased up to 100% following surgical removal of tumor further 
suggesting that presence of tumor correlates with elevated urinary Bcl-2 in OC 
patients. 
 
Patients at High Risk for OC May be Predisposed to Elevated Urinary Levels of 
Bcl-2. 
Though there was a tendency for elevated Bcl-2 levels with increasing 
tumor grade and stage, the differences were not statistically significant (Tables 5 
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Figure 20.  Urinary Bcl-2 decreases after cytoreductive surgery.  Urinary levels of Bcl-2 were measured in duplicate 
by ELISA from seven patients of the USF cohort prior to initial surgery (black bars) and within 2 weeks following their 
initial cytoreductive surgery (white bars).  The data are expressed as the mean ng/ml Bcl-2. 
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& 6). Likewise, urinary Bcl-2 levels did not appear to vary between cancer 
histotypes and serum creatinine measured at the time of urine collection 
indicated that elevated urinary Bcl-2 levels in cancer patients were not related to 
renal dysfunction (data not shown).  In addition, while elevated levels of Bcl-2 
could be detected in the serum of some OC patients (data not shown), serum 
levels of Bcl-2 did not detect OC as accurately as urinary levels of Bcl-2 perhaps 
due to the presence of confounding proteins in serum compared to urine. 
Further, comparison of clinical parameters also indicated that urinary Bcl-2 levels 
did not relate with patient age (data not shown). Though the overall average age 
from normal controls and benign samples were somewhat less than that from OC 
patients (Table 4), the age range among all samples was comparable. Similarly, 
urinary Bcl-2 levels did not correlate with tumor size measured at cytoreductive 
surgery (data not shown) and may reflect variation in tumor composition. 
However, initial analyses of benign gynecologic samples from the MDA cohort 
revealed a subset of 10 individuals with elevated urinary Bcl-2 above threshold 
levels (Fig. 21). Upon further examination, 8 of these were identified as 
individuals at risk of developing OC due to a familial history of breast and/or OC, 
previous treatment for breast cancer or BRCA mutations carriers. 
 
Urinary Bcl-2 Complements CA125 Measurements 
To address the potential for urinary Bcl-2 to serve as a biomarker for OC, 
urinary Bcl-2 was compared with CA125 values. Using 12 healthy controls and 
23 patients with OC from the USF cohort (Fig. 22), elevated urinary Bcl-2 
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Figure 21.  Patients at high risk may demonstrate elevated urinary Bcl-2 
levels.  Urinary samples from the MDA cohorts were examined by ELISA for Bcl-
2 levels in normal healthy controls or in individuals at high risk for OC and plotted 
as a scatter plot. 
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Figure 22.  Urinary Bcl-2 complements CA125.  Wherever possible, urinary levels of Bcl-2 expressed as ng/ml ± SE.  
(A) and blood levels of CA125 expressed as average U/ml (B) were measured by ELISA from the same healthy controls 
and OC patients (muc, mucinous; PP, primary peritoneal; serous, serous adenocarcinoma) prior to initial cytoreductive 
surgery from the USF cohort.  White bars indicate Bcl-2 levels < 1.8 ng/ml (A) and CA125 levels < 35 U/ml (B) while * 
indicates CA125 levels > 600 U/ml. 
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(>1.8ng/ml) was associated with 95% OC detection (Fig. 22A) correctly 
identifying 17/17 patients with serous adenocarcinoma, 4/4 patients with 
mucinous OC and 1/2 patients with primary peritoneal cancer as OC positive. 
None of the healthy controls had urinary Bcl-2 levels >1.8 ng/ml and were, then, 
correctly classified as cancer-negative. In contrast, CA125 levels >35 U/ml from 
matched samples identified 13/17 or 76% of patients with serous 
adenocarcinoma, 3/4 or 75% of patients with mucinous OC (though CA125 levels 
in these patients ranged between 41-43 U/ml somewhat above threshold CA125 
values), and 1/2 or 50% of patients with primary peritoneal cancer as cancer 
positive, while 2/12 or 16% of healthy controls were false positive (Fig. 22B). 
When urinary Bcl-2 levels were compared with CA125 values among eOC 
(N=17) and lOC (N=83) cancers collected from both USF and MDA cohorts, high 
urinary Bcl-2 was detected in 5 (29%) early and 60 (72%) late OCs compared 
with 13 (76%) and 76 (92%) CA125 measurements. However, combined urinary 
Bcl-2 and CA125 positivity in these groups increased to 14 (82%) and 82 (99%) 
detection of early and late cancer, respectively. In addition, comparison between 
urinary Bcl-2 and CA125 measurements revealed a Pearson correlation of 0.644, 
p<0.0001 indicative of strong complementarity. 
Interestingly, 7/8 samples collected from women with endometriosis, often 
a cause for false positive CA125 values, tested negative for urinary Bcl-2 while 
the remaining sample tested just at, but not above, the threshold level for urinary 
Bcl-2 (data not shown).  
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Discussion 
While apoptosis is an essential biological process for normal development 
and maintenance of tissue homeostasis, it is also involved in a number of 
pathologic conditions including tissue injury, degenerative diseases, 
immunological diseases and cancer [209]. Whether activated by membrane 
bound death receptors [210] or by stress-induced mitochondrial perturbation with 
subsequent cytochrome c release [211], activation of downstream caspases 
leads to stepwise cellular destruction by disrupting the cytoskeleton, shutting 
down DNA replication and repair, degrading chromosomal DNA, and, finally, 
disintegrating the cell into apoptotic bodies [212]. The key regulators of apoptosis 
include members of the bcl-2 protein family [213]. 
The bcl-2 protein family consists of both pro- and anti-apoptotic protein 
family members that act at different levels of the apoptotic cascade to regulate 
apoptosis. The bcl-2 family members contain at least one Bcl-2-homology (BH) 
domain [213]. Though all bcl-2 family members demonstrate membrane channel 
forming activity, Bcl-2 (the archetypal bcl-2 family member) channels are cation 
(Ca++) selective and, owing to its ER and mitochondrial membrane localization 
[214], the anti-apoptotic function of Bcl-2 is at least partly mediated by its ability 
to prevent calcium release from the ER and subsequent mitochondrial membrane 
perturbation and cytochrome c release. Since Bcl-2 is overexpressed in many 
tumor types including OC [59, 215], it contributes to chemoresistance by 
stabilizing the mitochondrial membrane against apoptotic insults. Currently, 
preclinical studies focused on the development of agents to inhibit Bcl-2 include 
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antisense oligonucleotides such as G3,139 [216] and small molecular inhibitors 
of Bcl-2 [217]. 
In addition to promoting cancer cell survival by promoting resistance to 
apoptosis, recent studies indicate that Bcl-2 overexpression may also promote 
cancer cell survival through increased angiogenesis by upregulating VEGF 
expression [169]. Specifically, Bcl-2 mediates VEGF transcription in a Hif-1-
dependent manner and enhances VEGF mRNA stabilization [218]. 
Consequently, targeting Bcl-2 for therapeutic intervention may also complement 
anti-angiogenic therapies.  
In contrast to therapeutic targeting, my data suggest that Bcl-2 
overexpression may result in increased levels of Bcl-2 in bodily fluids that could 
represent a novel biomarker for OC.  Specifically, data from two separate cohorts 
indicated significantly elevated urinary Bcl-2 among OC patients compared to 
healthy controls or women with benign gynecologic disease. While minor 
differences existed between urinary Bcl-2 levels in the two cohorts examined, 
these may reflect differences in cohort size, differences in initial sample storage 
temperatures, length of sample storage, number of repeated freeze thaws or 
necessity for addition of protease inhibitors for sample testing. However, the 
similarity of Bcl-2 values among samples in both cohorts (e.g. USF healthy 0.30 
ng/ml & MDA healthy 0.69 ng/ml or USF cancer 2.54 ng/ml and MDA cancer 2.30 
ng/ml) appears to validate my hypothesis. Interestingly, though the number of 
samples available from eOC was small, the lack of statistical differences in 
urinary Bcl-2 levels between eOC and lOC suggests that urinary Bcl-2 may be 
95 
 
useful for early detection of OC. Further, the most apparent clinical features 
related to elevated urinary Bcl-2 are high risk for disease and complementarity 
with CA125. While the former represents an important target group, the latter 
suggests potentially important diagnostic and prognostic roles for urinary Bcl-2. 
By helping to discern between OC and false positive CA125 values arising from 
other conditions, urinary Bcl-2 measurements may improve detection of early 
stage OC. Given the only association between urinary Bcl-2 and cancer reported 
to date describes the presence of methylated urinary Bcl-2 DNA in urine 
sediments associated with bladder cancer [219, 220], development of urinary 
Bcl-2 protein testing could provide a convenient and non-invasive strategy for 
detection/screening of OC. Clearly, further studies are warranted to verify the 
potential for urinary levels of Bcl-2 to serve as a biomarker alone or in 
combination with other markers, especially as that may pertain to screening for 
OC.  
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CHAPTER V: 
CONCLUDING REMARKS 
 
OC is the leading cause of gynecologic cancer-related deaths in the 
United States [1].  OC is usually asymptomatic and currently lacks a routine 
screening available to the general public.  Therefore, an alarming number of OC 
patients are diagnosed once the disease has reached advanced stages, leading 
to challenges in treatment and, ultimately, poor prognoses [7].  Bcl-2 
overexpression is often seen in OC patients and it has been suggested that this 
protein contributes to neoplastic growth by its ability to inhibit apoptosis [48].  
Therefore, it is of importance to further investigate the mechanisms provoking 
overexpression of Bcl-2 in OC and the extra-anti-apoptotic roles that it may be 
playing in this disease. 
This study (Chapter 2) began by characterizing the correlation between 
Bcl-2 expression and OC progression.  Immunohistochemistry revealed 
differential cytoplasmic Bcl-2 expression among tissue specimens from healthy 
volunteers, patients with various benign gynecologic diseases, and OC patients.  
Expression levels of both epithelial and stromal Bcl-2 decreased in extent and 
intensity with OC progression.  These findings are in agreement with previous 
studies [56, 131, 132], suggesting that Bcl-2 is present and important in the 
earlier stages of ovarian carcinogenesis.  Notably, Bcl-2 can undergo 
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modifications resulting in enhanced anti-apoptotic activity (i.e. phosphorylation) 
[221, 222], or formation of a proteolytic pro-apoptotic fragment (i.e. caspase 3 
cleavage) [223].  While one could speculate that decreases seen in tissue Bcl-2 
expression with OC progression in the present study arose by Bcl-2 undergoing 
one of the aforementioned posttranslational modifications, an alternative 
explanation tested in chapter 3 is that Bcl-2 was secreted by OC cells.  
Additionally, my immunohistochemical studies showed increased lymphocyte 
infiltration with OC progression, which may represent yet another extra anti-
apoptotic function of Bcl-2 besides contributing to aberrant angiogenesis 
(Chapter 3). 
This study (Chapter 3) also investigated the mechanism by which Bcl-2 is 
overexpressed in OC and found that LPA significantly upregulates Bcl-2 in OC 
cell lines.  Additionally, further experimentation led to the novel finding that LPA 
increases secretion of Bcl-2 from OC cell lines.  This is especially interesting 
because our lab has previously shown that LPA mediates upregulation of 
telomerase in a VEGF-dependent manner [197].  Because ovarian tumors 
frequently metastasize to the omentum, and myofibroblasts play important roles 
during cancer progression and metastasis [224-226], it is of interest to note that 
LPA from cancer cells stimulates differentiation of human adipose tissue-derived 
mesenchymal stem cells to myofibroblast cells [227] as well as their secretion of 
VEGF and stromal cell-derived factor-1 (SDF-1) [228].  Moreover, 
myofibroblasts-derived SDF-1 recruits endothelial progenitor cells into tumors, 
thereby stimulating neoangiogenesis [229].  Additionally, VEGF protects 
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endothelial cells from cell death and sustains angiogenesis by increasing Bcl-2 
expression [198].  Herein, OC-derived extracellular Bcl-2 facilitated aberrant 
endothelial tube formation, suggesting a paracrine pathway in which Bcl-2 
functions to further enhance ovarian tumor progression (Figure 23).  
Paradoxically, then, while tumor cells stimulate angiogenic factors that enhance 
tumor growth and survival (i.e. through LPA upregulation of VEGF), dysregulated 
tumor-mediated angiogenesis, potentially, in part, due to extracellular Bcl-2, 
leads to aberrant vasculature, contributing to ascites formation and dissemination 
of tumor cells.  Taken together these findings provide more information about 
cross-talk between tumor and endothelial cells that is essential for perpetuation 
of tumor growth.  Due to the heterogeneous population of stromal cell 
components in ovarian tumors and the various cell types on which LPA, VEGF, 
and Bcl-2 act, further OC 3D culture or animal model studies are warranted to 
better understand how these proteins interact to modulate normal and/or 
abnormal angiogenesis in vivo. 
As previously mentioned, the lack of a diagnostic screening tool 
contributes to the poor prognosis associated with OC.  Ideally, the diagnostic test 
would be minimally invasive, utilizing serum, or completely non-invasive, using 
urine, and would provide a sensitivity, specificity, and positive predictive value 
higher than that of CA125.  Proteomics-based technology is at the forefront in 
discovery of novel biomarkers for development of an early stage OC diagnostic 
tool.  Over the years, several serum proteins have been proposed as potential 
biomarkers for OC including HE4[230], LPA [89], osteopontin [231], mesothelin 
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Figure 23.  Schematic representation of LPA-induced Bcl-2 overexpression 
and secretion in OC cell leading to novel actions of secreted Bcl-2 on 
endothelial cells.  Our lab has previously shown that LPA induces telomerase 
activity in a VEGF-dependent manner which can be inhibited by Vitamin E.  
Chapter 3 showed that LPA increased Bcl-2 expression and secretion in OC cells 
in a transcription-dependent manner.  Extracellular Bcl-2 was then shown to 
promote aberrant tube formation by inhibition of endothelial cell migration.  
Chapter 4 showed that secreted Bcl-2 could be detected in urine of OC patients.  
 
100 
 
[232], apolipoprotein A1[233], transthyretin [233], and transferrin [233].  While 
urinary biomarkers have been used for diagnosis and prognosis of urological 
malignancies for some time, urinary biomarkers for OC have recently piqued 
interest due to the presence of fewer confounding proteins and improved protein 
stability in urine compared to serum [234].  Recently, mesothelin [208], 
angiostatin [235], and HE4 [236]  have been identified as promising urinary 
biomarkers for early stage OC.  Additionally, urine metabolites have been 
implicated in detection of early stage breast and OC [237], suggesting 
metabolomics as another useful tool in the quest for cancer biomarkers.  Despite 
the promise of these studies, no single biomarker, or combination of markers, 
has exhibited the criteria required to be designated as diagnostic marker(s) for 
OC.  Bcl-2 secretion by OC cells in vitro herein suggested that Bcl-2 secreted by 
OC cells in vivo could be detected in bodily fluids and be clinically useful.  I found 
elevated urinary Bcl-2 levels in women with OC.  Notably, urinary Bcl-2 was 
elevated in samples from patients with both early and late stage OC, and was 
complementary when compared to CA125 levels in parallel.  Additionally, urinary 
Bcl-2 was significantly lower in benign samples versus cancer samples.  Other 
apoptosis-related proteins found in urine include inhibin and activin, with 
implications as a biomarker for severe pre-eclampsia in pregnant women [238], 
and a risk assessment tool for hypoxic ischemic encephalopathy in newborns 
[239], respectively.  Altogether, these findings suggest that urinary Bcl-2, alone, 
or in combination with other biomarkers may be a non-invasive, cost-effective 
screening tool for OCs, including those at early stages.   
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Collectively, this study demonstrates that Bcl-2 plays multifaceted roles in 
OC progression and may be a potential biomarker to improve detection of early 
stage OC.  Hence, further understanding of the mechanisms by which Bcl-2 
regulates the growth of OC cells and affects tumor angiogenesis through its anti-
apoptotic and extra anti-apoptotic functions will lead to improved diagnostic and 
treatment strategies for OC.
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